{
    "title": "Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation",
    "url": "https://openalex.org/W3119598339",
    "year": 2021,
    "authors": [
        {
            "id": null,
            "name": "Alquezar, Carolina",
            "affiliations": [
                "University of California, San Francisco",
                "University Memory and Aging Center"
            ]
        },
        {
            "id": "https://openalex.org/A2744875220",
            "name": "Arya Shruti",
            "affiliations": [
                "University Memory and Aging Center",
                "University of California, San Francisco"
            ]
        },
        {
            "id": null,
            "name": "Kao, Aimee W",
            "affiliations": [
                "University of California, San Francisco",
                "University Memory and Aging Center"
            ]
        }
    ],
    "references": [
        "https://openalex.org/W1568341953",
        "https://openalex.org/W2800613882",
        "https://openalex.org/W2792393524",
        "https://openalex.org/W2123322767",
        "https://openalex.org/W2119693327",
        "https://openalex.org/W1991017805",
        "https://openalex.org/W2107677817",
        "https://openalex.org/W2049391304",
        "https://openalex.org/W1600934558",
        "https://openalex.org/W2617946428",
        "https://openalex.org/W1981662243",
        "https://openalex.org/W2537825497",
        "https://openalex.org/W2121418448",
        "https://openalex.org/W1971125966",
        "https://openalex.org/W2084345267",
        "https://openalex.org/W2207904128",
        "https://openalex.org/W2011634611",
        "https://openalex.org/W2040351396",
        "https://openalex.org/W2058989808",
        "https://openalex.org/W2155048015",
        "https://openalex.org/W2519516239",
        "https://openalex.org/W2810998522",
        "https://openalex.org/W2799939919",
        "https://openalex.org/W2112136536",
        "https://openalex.org/W2048332130",
        "https://openalex.org/W2149168676",
        "https://openalex.org/W1978012364",
        "https://openalex.org/W2112874709",
        "https://openalex.org/W1998087666",
        "https://openalex.org/W1762366815",
        "https://openalex.org/W1964504843",
        "https://openalex.org/W2635415917",
        "https://openalex.org/W1501075116",
        "https://openalex.org/W1978668412",
        "https://openalex.org/W2107339320",
        "https://openalex.org/W2070971554",
        "https://openalex.org/W2124121545",
        "https://openalex.org/W2909537089",
        "https://openalex.org/W2143829202",
        "https://openalex.org/W2073688317",
        "https://openalex.org/W2148570557",
        "https://openalex.org/W2159188744",
        "https://openalex.org/W3024435024",
        "https://openalex.org/W2099795098",
        "https://openalex.org/W2108741722",
        "https://openalex.org/W2151003489",
        "https://openalex.org/W1532265037",
        "https://openalex.org/W2039468514",
        "https://openalex.org/W2185034389",
        "https://openalex.org/W2415969802",
        "https://openalex.org/W2138070279",
        "https://openalex.org/W2136221184",
        "https://openalex.org/W2751201591",
        "https://openalex.org/W2088983023",
        "https://openalex.org/W1541944730",
        "https://openalex.org/W2091014617",
        "https://openalex.org/W1528790659",
        "https://openalex.org/W1893543180",
        "https://openalex.org/W2139553041",
        "https://openalex.org/W2137337037",
        "https://openalex.org/W2075917280",
        "https://openalex.org/W1968553823",
        "https://openalex.org/W2061538653",
        "https://openalex.org/W1978278560",
        "https://openalex.org/W1495788363",
        "https://openalex.org/W2431163235",
        "https://openalex.org/W2786527187",
        "https://openalex.org/W2002698073",
        "https://openalex.org/W2901164269",
        "https://openalex.org/W2320241962",
        "https://openalex.org/W1983523416",
        "https://openalex.org/W2013037750",
        "https://openalex.org/W2790231974",
        "https://openalex.org/W2741056309",
        "https://openalex.org/W1998344552",
        "https://openalex.org/W2052458891",
        "https://openalex.org/W1032333588",
        "https://openalex.org/W2182763281",
        "https://openalex.org/W2997680311",
        "https://openalex.org/W3005989107",
        "https://openalex.org/W2894821853",
        "https://openalex.org/W2039392338",
        "https://openalex.org/W2855956231",
        "https://openalex.org/W2326962045",
        "https://openalex.org/W1965402821",
        "https://openalex.org/W2164226163",
        "https://openalex.org/W2034614265",
        "https://openalex.org/W2155022431",
        "https://openalex.org/W2166987747",
        "https://openalex.org/W2136506445",
        "https://openalex.org/W2590813565",
        "https://openalex.org/W2101090646",
        "https://openalex.org/W2052302154",
        "https://openalex.org/W1963967499",
        "https://openalex.org/W2124975942",
        "https://openalex.org/W3036210937",
        "https://openalex.org/W3015784636",
        "https://openalex.org/W2553689505",
        "https://openalex.org/W2091829752",
        "https://openalex.org/W2074690689",
        "https://openalex.org/W2168079270",
        "https://openalex.org/W1987927755",
        "https://openalex.org/W2044236802",
        "https://openalex.org/W2026938943",
        "https://openalex.org/W2107114877",
        "https://openalex.org/W2007442181",
        "https://openalex.org/W2579528010",
        "https://openalex.org/W2012781495",
        "https://openalex.org/W2005759199",
        "https://openalex.org/W2026263038",
        "https://openalex.org/W2046720254",
        "https://openalex.org/W2029874231",
        "https://openalex.org/W1990573749",
        "https://openalex.org/W1529133753",
        "https://openalex.org/W6628364630",
        "https://openalex.org/W2031259748",
        "https://openalex.org/W2024935012",
        "https://openalex.org/W1999054610",
        "https://openalex.org/W2136956610",
        "https://openalex.org/W1971358793",
        "https://openalex.org/W1987211450",
        "https://openalex.org/W2094423062",
        "https://openalex.org/W1993287528",
        "https://openalex.org/W2789994371",
        "https://openalex.org/W1997920940",
        "https://openalex.org/W1998634021",
        "https://openalex.org/W1996406602",
        "https://openalex.org/W2022285303",
        "https://openalex.org/W2922673442",
        "https://openalex.org/W2167435540",
        "https://openalex.org/W4293086341",
        "https://openalex.org/W2152656267",
        "https://openalex.org/W2615638297",
        "https://openalex.org/W2809094767",
        "https://openalex.org/W4212766227",
        "https://openalex.org/W2166086677",
        "https://openalex.org/W2462787445",
        "https://openalex.org/W2744353305",
        "https://openalex.org/W2969612253",
        "https://openalex.org/W2019219179",
        "https://openalex.org/W2147718170",
        "https://openalex.org/W2040470885",
        "https://openalex.org/W2990428470",
        "https://openalex.org/W2613539552",
        "https://openalex.org/W2921437380",
        "https://openalex.org/W2763925507",
        "https://openalex.org/W1982533712",
        "https://openalex.org/W1972375269",
        "https://openalex.org/W2123314342",
        "https://openalex.org/W2117398821",
        "https://openalex.org/W1571862215",
        "https://openalex.org/W1979729411",
        "https://openalex.org/W2084655660",
        "https://openalex.org/W2164029759",
        "https://openalex.org/W2049020770",
        "https://openalex.org/W1994396628",
        "https://openalex.org/W2018639404",
        "https://openalex.org/W1975320495",
        "https://openalex.org/W2129495914",
        "https://openalex.org/W2096913878",
        "https://openalex.org/W2625848618",
        "https://openalex.org/W1836469884",
        "https://openalex.org/W2609844681",
        "https://openalex.org/W2343995064",
        "https://openalex.org/W2066371153",
        "https://openalex.org/W1964358104",
        "https://openalex.org/W2023170511",
        "https://openalex.org/W1985696068",
        "https://openalex.org/W4655498",
        "https://openalex.org/W190025346",
        "https://openalex.org/W2040714286",
        "https://openalex.org/W2032101254",
        "https://openalex.org/W1974906557",
        "https://openalex.org/W2164933850",
        "https://openalex.org/W2163669036",
        "https://openalex.org/W2005524096",
        "https://openalex.org/W2071292969",
        "https://openalex.org/W2068751031",
        "https://openalex.org/W2112698509",
        "https://openalex.org/W2166747071",
        "https://openalex.org/W2510751088",
        "https://openalex.org/W2059102250",
        "https://openalex.org/W2129868478",
        "https://openalex.org/W2892213316",
        "https://openalex.org/W2142060886",
        "https://openalex.org/W2062044361",
        "https://openalex.org/W2185439968",
        "https://openalex.org/W2026851735",
        "https://openalex.org/W2332713519",
        "https://openalex.org/W2094196864",
        "https://openalex.org/W2168994316",
        "https://openalex.org/W2790500393",
        "https://openalex.org/W2951509935",
        "https://openalex.org/W1249061998",
        "https://openalex.org/W2133190342",
        "https://openalex.org/W2074059686",
        "https://openalex.org/W2125172225",
        "https://openalex.org/W1483889845",
        "https://openalex.org/W2110862168",
        "https://openalex.org/W2092607846",
        "https://openalex.org/W4241168058",
        "https://openalex.org/W2017945532",
        "https://openalex.org/W2008219426",
        "https://openalex.org/W1997426613",
        "https://openalex.org/W1985351513",
        "https://openalex.org/W2032879521",
        "https://openalex.org/W2100026237",
        "https://openalex.org/W2151078743",
        "https://openalex.org/W2000655392",
        "https://openalex.org/W2061864873",
        "https://openalex.org/W2899521216",
        "https://openalex.org/W2000608506",
        "https://openalex.org/W2079376696",
        "https://openalex.org/W2001752726",
        "https://openalex.org/W2082944527",
        "https://openalex.org/W2018173903",
        "https://openalex.org/W2148814198",
        "https://openalex.org/W2171235356",
        "https://openalex.org/W1992925196",
        "https://openalex.org/W2940059884",
        "https://openalex.org/W2113352370",
        "https://openalex.org/W2087004359",
        "https://openalex.org/W2022402045",
        "https://openalex.org/W1970354788",
        "https://openalex.org/W2017720176",
        "https://openalex.org/W2067469800",
        "https://openalex.org/W2123440554",
        "https://openalex.org/W2049274499",
        "https://openalex.org/W2004503735",
        "https://openalex.org/W2067309491",
        "https://openalex.org/W2913940235",
        "https://openalex.org/W2769952960",
        "https://openalex.org/W2905907974",
        "https://openalex.org/W2947390945",
        "https://openalex.org/W1991714330",
        "https://openalex.org/W2089551665",
        "https://openalex.org/W2035892035",
        "https://openalex.org/W2150123812",
        "https://openalex.org/W2016151751",
        "https://openalex.org/W2178503716",
        "https://openalex.org/W2035417449",
        "https://openalex.org/W2149107089",
        "https://openalex.org/W2002659179",
        "https://openalex.org/W2162184208",
        "https://openalex.org/W2091857357",
        "https://openalex.org/W1538925586",
        "https://openalex.org/W1986413832",
        "https://openalex.org/W2105796226",
        "https://openalex.org/W1997369314",
        "https://openalex.org/W2021242983",
        "https://openalex.org/W2762703026",
        "https://openalex.org/W2133548029",
        "https://openalex.org/W2085939493",
        "https://openalex.org/W2013581014",
        "https://openalex.org/W2059018787",
        "https://openalex.org/W2117695104",
        "https://openalex.org/W6779742790",
        "https://openalex.org/W2889255537",
        "https://openalex.org/W2043882563",
        "https://openalex.org/W2076032638",
        "https://openalex.org/W2122699281",
        "https://openalex.org/W1919353",
        "https://openalex.org/W2290722071",
        "https://openalex.org/W2011134915",
        "https://openalex.org/W2020539883",
        "https://openalex.org/W1983119108",
        "https://openalex.org/W1987208492",
        "https://openalex.org/W2064899413",
        "https://openalex.org/W2110466970",
        "https://openalex.org/W2583700773",
        "https://openalex.org/W1525659758",
        "https://openalex.org/W2020209643",
        "https://openalex.org/W2104034347",
        "https://openalex.org/W2076834744",
        "https://openalex.org/W1973897761",
        "https://openalex.org/W1970577444",
        "https://openalex.org/W2614053601",
        "https://openalex.org/W2950980718",
        "https://openalex.org/W3037848823",
        "https://openalex.org/W2796637563",
        "https://openalex.org/W2727929522",
        "https://openalex.org/W3005492459",
        "https://openalex.org/W2923034350",
        "https://openalex.org/W3005583156",
        "https://openalex.org/W1989347577",
        "https://openalex.org/W2078658743",
        "https://openalex.org/W2060204934",
        "https://openalex.org/W1971931529",
        "https://openalex.org/W2047163245",
        "https://openalex.org/W2595098178",
        "https://openalex.org/W2082853151",
        "https://openalex.org/W2002900801",
        "https://openalex.org/W2104962265",
        "https://openalex.org/W2036911946",
        "https://openalex.org/W2091893114",
        "https://openalex.org/W2051494500",
        "https://openalex.org/W2054590983",
        "https://openalex.org/W2061419784",
        "https://openalex.org/W2605036205",
        "https://openalex.org/W2069620193",
        "https://openalex.org/W2792694489",
        "https://openalex.org/W2279268939",
        "https://openalex.org/W2018423808",
        "https://openalex.org/W2088433073",
        "https://openalex.org/W2058500063",
        "https://openalex.org/W2006520473",
        "https://openalex.org/W2013743510",
        "https://openalex.org/W2094848622",
        "https://openalex.org/W2070679875",
        "https://openalex.org/W3102160053",
        "https://openalex.org/W2618553145",
        "https://openalex.org/W1989856924",
        "https://openalex.org/W4210982731",
        "https://openalex.org/W1523693806",
        "https://openalex.org/W3107242996",
        "https://openalex.org/W3035387162",
        "https://openalex.org/W2004499293",
        "https://openalex.org/W2082429191",
        "https://openalex.org/W2949460676",
        "https://openalex.org/W2166028744"
    ],
    "abstract": "Post-translational modifications (PTMs) on tau have long been recognized as affecting protein function and contributing to neurodegeneration. The explosion of information on potential and observed PTMs on tau provides an opportunity to better understand these modifications in the context of tau homeostasis, which becomes perturbed with aging and disease. Prevailing views regard tau as a protein that undergoes abnormal phosphorylation prior to its accumulation into the toxic aggregates implicated in Alzheimer's disease (AD) and other tauopathies. However, the phosphorylation of tau may, in fact, represent part of the normal but interrupted function and catabolism of the protein. In addition to phosphorylation, tau undergoes another forms of post-translational modification including (but not limited to), acetylation, ubiquitination, glycation, glycosylation, SUMOylation, methylation, oxidation, and nitration. A holistic appreciation of how these PTMs regulate tau during health and are potentially hijacked in disease remains elusive. Recent studies have reinforced the idea that PTMs play a critical role in tau localization, protein-protein interactions, maintenance of levels, and modifying aggregate structure. These studies also provide tantalizing clues into the possibility that neurons actively choose how tau is post-translationally modified, in potentially competitive and combinatorial ways, to achieve broad, cellular programs commensurate with the distinctive environmental conditions found during development, aging, stress, and disease. Here, we review tau PTMs and describe what is currently known about their functional impacts. In addition, we classify these PTMs from the perspectives of protein localization, electrostatics, and stability, which all contribute to normal tau function and homeostasis. Finally, we assess the potential impact of tau PTMs on tau solubility and aggregation. Tau occupies an undoubtedly important position in the biology of neurodegenerative diseases. This review aims to provide an integrated perspective of how post-translational modifications actively, purposefully, and dynamically remodel tau function, clearance, and aggregation. In doing so, we hope to enable a more comprehensive understanding of tau PTMs that will positively impact future studies.",
    "full_text": "REVIEW\npublished: 07 January 2021\ndoi: 10.3389/fneur.2020.595532\nFrontiers in Neurology | www.frontiersin.org 1 January 2021 | Volume 11 | Article 595532\nEdited by:\nSonia Do Carmo,\nMcGill University, Canada\nReviewed by:\nChaur-Jong Hu,\nTaipei Medical University, Taiwan\nIsabelle Landrieu,\nINSERM U1167 Facteurs de risque et\ndéterminants moléculaires des\nmaladies liées au\nvieillissement, France\n*Correspondence:\nAimee W. Kao\naimee.kao@ucsf.edu\n†These authors have contributed\nequally to this work\nSpecialty section:\nThis article was submitted to\nDementia and Neurodegenerative\nDiseases,\na section of the journal\nFrontiers in Neurology\nReceived: 16 August 2020\nAccepted: 07 December 2020\nPublished: 07 January 2021\nCitation:\nAlquezar C, Arya S and Kao AW\n(2021) Tau Post-translational\nModiﬁcations: Dynamic Transformers\nof Tau Function, Degradation, and\nAggregation.\nFront. Neurol. 11:595532.\ndoi: 10.3389/fneur.2020.595532\nTau Post-translational Modiﬁcations:\nDynamic Transformers of Tau\nFunction, Degradation, and\nAggregation\nCarolina Alquezar†, Shruti Arya† and Aimee W. Kao*\nDepartment of Neurology, Memory and Aging Center, Universi ty of California, San Francisco, San Francisco, CA,\nUnited States\nPost-translational modiﬁcations (PTMs) on tau have long be en recognized as affecting\nprotein function and contributing to neurodegeneration. T he explosion of information\non potential and observed PTMs on tau provides an opportunit y to better understand\nthese modiﬁcations in the context of tau homeostasis, which becomes perturbed\nwith aging and disease. Prevailing views regard tau as a prot ein that undergoes\nabnormal phosphorylation prior to its accumulation into th e toxic aggregates implicated\nin Alzheimer’s disease (AD) and other tauopathies. However , the phosphorylation of\ntau may, in fact, represent part of the normal but interrupte d function and catabolism\nof the protein. In addition to phosphorylation, tau undergo es another forms of post-\ntranslational modiﬁcation including (but not limited to), acetylation, ubiquitination,\nglycation, glycosylation, SUMOylation, methylation, oxi dation, and nitration. A holistic\nappreciation of how these PTMs regulate tau during health an d are potentially hijacked\nin disease remains elusive. Recent studies have reinforced the idea that PTMs play\na critical role in tau localization, protein-protein inter actions, maintenance of levels,\nand modifying aggregate structure. These studies also prov ide tantalizing clues into\nthe possibility that neurons actively choose how tau is post -translationally modiﬁed,\nin potentially competitive and combinatorial ways, to achi eve broad, cellular programs\ncommensurate with the distinctive environmental conditio ns found during development,\naging, stress, and disease. Here, we review tau PTMs and desc ribe what is currently\nknown about their functional impacts. In addition, we class ify these PTMs from the\nperspectives of protein localization, electrostatics, an d stability, which all contribute\nto normal tau function and homeostasis. Finally, we assess t he potential impact of\ntau PTMs on tau solubility and aggregation. Tau occupies an u ndoubtedly important\nposition in the biology of neurodegenerative diseases. Thi s review aims to provide an\nintegrated perspective of how post-translational modiﬁca tions actively, purposefully, and\ndynamically remodel tau function, clearance, and aggregat ion. In doing so, we hope\nto enable a more comprehensive understanding of tau PTMs tha t will positively impact\nfuture studies.\nKeywords: phosphorylation, acetylation, ubiquitination , methylation, sumoylation, glycosylation, glycation,\nproteolysis\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\nINTRODUCTION\nPost-translational modiﬁcations (PTMs) refer to the\nmodiﬁcations that occur in a protein either shortly after its\ntranslation by ribosomes or after its folding and localizat ion\nare complete (\n1). These modiﬁcations are usually catalyzed by\nenzymes and involve the addition of chemical groups, sugars,\nor proteins to speciﬁc residues of the targeted protein. Nearly\nall cellular processes can be regulated via PTMs. Therefore,\nPTMs provide a means for the natural increase in the proteome\ncomplexity and allow one gene to encode a variety of distinct\nprotein molecules with distinct functional roles, known as\nproteoforms (\n2). PTMs alter the charge and hydrophobicity\n(electrostatics) of a protein, which in turn induces structu ral\nchanges that inﬂuence protein function, protein-protein\ninteractions, and protein aggregation (\n3, 4). In this way, PTMs\nalso can aﬀect the clearance of proteins by regulating the\nfunctionality of degrons, peptide sequences that target a prot ein\nfor degradation (\n5). Essentially all proteins in eukaryotes,\nincluding the “intrinsically disordered” or “natively unfo lded”\nproteins that tend to aggregate in neurodegenerative diseas es,\nare susceptible to PTMs ( 3, 6, 7). Unlike folded proteins, natively\nunfolded proteins do not have a well-deﬁned three-dimension al\nstructure and exist as an ensemble of dynamically ﬂuctuatin g\nconformations. The lack of tertiary structure makes native ly\nunfolded proteins more vulnerable to PTMs ( 8).\nTau is a classic example of a natively unfolded protein ( 7, 9)\nthat can be modiﬁed by a myriad of PTMs. Tau is a microtubule-\nbinding protein found in neurons and glial cells, and is primar ily\ninvolved in the stabilization of the cytoskeleton (\n10). Based on\nits interaction with microtubules and on the basis of its ami no\nacid composition, the primary structure of tau can be divided\ninto an N-terminal projection domain, a proline-rich region, a\nrepeat region, and a C-terminal domain (\n11) ( Figure 1). Tau\nhas six diﬀerent isoforms in human brain that diﬀer from each\nother in the number of N-terminal inserts and either contain\nor lack one repeat (R2) of the four repeats (R1-R4) present in\nthe microtubule-binding domain region. Because of its abil ity to\nbind to microtubules, the main function of tau is thought to b e\nthe modulation of microtubule dynamics, which consequentl y\naﬀects neurite outgrowth, axonal transport, and synapsis (\n12–\n14). Recent studies have shown that tau also interacts with\nseveral cell membranes, including the plasma membrane, the\nendoplasmic reticulum, and Golgi (\n15–17). Tau may also regulate\nintracellular signaling cascade via interactions with prot eins such\nas 14.3.3, Pin-1, and Fyn ( 18), suggesting a role for tau in cell\nsignaling ( 18). Although tau is primarily an axonal protein, it\ncan be found within neuronal nuclei where it binds to either\nDNA or RNA and regulates gene expression (\n19–21). Under\ncertain pathological circumstances, tau loses its function as a\nmicrotubule-binding protein and accumulates in the cytosol\nof aﬀected cells, forming ﬁrst “pre-tangles” and then insolub le\ncytosolic inclusions or aggregates composed of ﬁbrillar form s of\ntau known as neuroﬁbrillary tangles (NFTs).\nDiseases associated with the presence of tau inclusions in\nthe brain are collectively referred to as tauopathies and inc lude\na diverse group of neurodegenerative diseases with distinc t\npathological characteristics ( Figure 1). Tau-immunopositive\nintracellular aggregates are the pathognomonic hallmark of\ntauopathies (\n22). However, the forces driving tau, especially\nnon-mutant, wild-type tau, into intracellular aggregates are\nincompletely understood. The cellular protein homeostasis (o r\nproteostasis) network is fundamental to the proper functionin g\nof tau and prevents the accumulation of tau aggregates. In\nprinciple, proteostasis encompasses the entire life cycle of a\nprotein such as tau, including synthesis, proper folding, post-\ntranslational processing, and degradation. Thus, PTMs are a k ey\ncontributor to tau proteostasis and thereby could regulate ta u\nfunction, levels, and aggregation.\nThe same PTMs that regulate tau function also have the\nability to induce alterations in its clearance, conformatio n, and\naggregation potential (\n23). However, not all tau PTMs are\n“pathological”. Many PTMs have been identiﬁed in tau extracte d\nfrom healthy brains, suggesting a normal role for PTMs in tau\nfunction (\n24). Among all tau PTMs, phosphorylation is the\nmost studied, and traditionally, it was thought that increa sed\nphosphorylation was the trigger for tau intracellular aggregat ion\n(25). However, a growing body of evidence suggests that other\nPTMs also considerably regulate tau function and may even\nprecede phosphorylation in the sequence of events leading to tau\ninclusions formation.\nIn this review, we ﬁrst provide a synopsis of the many\ntau PTMs that impact its function and potentially contribute\nto dysfunction (section Eﬀects of PTMs on Tau Function\nand Dysfunction). We then fold this information into an\nintegrated discussion of how PTMs can regulate tau degradati on\n(section Eﬀect of PTMs on Tau Degradation) and aggregation\n(section Eﬀect of PTMs on Tau Solubility and Aggregation). A\nrarely discussed but critically important subject, cross-t alk, and\ncompetition between PTMs, is considered next (section Cross-\nTalk and Competition Between PTMs). Finally, we summarize\nstrengths and limitations of current approaches to the study\nof PTMs (section Approaches and Limitations) and provide\nconcluding remarks (section Concluding Remarks).\nEFFECTS OF PTMs ON TAU FUNCTION\nAND DYSFUNCTION\nThe main role of PTM addition to any protein, including\ntau, is to regulate and increase functional diversity usually\nby altering electrostatics and/or structure. Approximately 35\npercent of the amino acid residues in tau are susceptible to\nmodiﬁcation peri- or post-translationally. These residues a re\nserine (S), threonine (T), tyrosine (Y), lysine (K), arginine (R),\nasparagine (N), histidine (H), and cysteine (C). Like other\nproteins, tau undergoes PTMs that involve the addition of\nsmall chemical groups or peptides on diﬀerent side chains of\ntau: phosphorylation on S, T, or Y; acetylation, ubiquitinatio n,\nSUMOylation, and glycation on K; methylation on K or R;\nO-GlcNAcylation on S and T, N-glycosylation on nitrogens,\nnitration on Y and oxidation on carbons ( Figure 2). Tau can\nalso undergo protonation on histidine residues and proteolyt ic\ncleavage (or truncation), although these modiﬁcations are often\nFrontiers in Neurology | www.frontiersin.org 2 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\nFIGURE 1 | Post-translational modiﬁcations are found throughout tau a nd associate with all tauopathies. (A) Schematic representation of the structural features of\n2N4R tau protein. Tau exists in 6 isoforms generated by the al ternative splicing of exons 2, 3, and 10 of the MAPT gene. The i soforms include 0, 1, or 2\namino-terminal inserts (blue rectangles) and three (3R) or four (4R) microtubule-binding potential repeat domains (g reen rectangles). (B) Pathological and genetic\nclassiﬁcation of tauopathies as they relate to post-transla tional modiﬁcations (PTMs). Primary tauopathies fall under the umbrella pathological term frontotemporal\nlobar degeneration with tau inclusions (FTLD-Tau) and incl ude Pick’s disease (PiD), progressive supranuclear palsy ( PSP), corticobasal degeneration (CBD), and\nfrontotemporal dementia with parkinsonism (FTDP-17). Alz heimer’s disease, a secondary or mixed tauopathy, is charac terized by the presence of extracellular\ninclusions containing Amyloid β (Aβ ) protein. Tauopathies are also classiﬁed depending on tau is oform composing the intracellular inclusions. PiD is a 3R-p redominat\ntauopathy, PSP , and CBD are 4R tauopathies and FTDP-17 and AD are 3R:4R tauopathies. The PTMs observed in tau, the targete d residues and the disease where\nthey have been observed is also shown.\nnot considered alongside traditional PTMs. The implications of\nall of these modiﬁcations will be discussed in this section.\nThe clustering of PTMs within short sequence motifs and\nfunctional domains suggests that tau function and subcellu lar\nlocalization could be regulated by a complex interplay between\ndiﬀerent PTMs ( Figure 3). Since some modiﬁcations have been\nfound only in the tau aggregates associated with disease (\n26, 27),\nit has been suggested that these modiﬁcations may be regulat ing\ntau dysfunction. Although a hypothetical sequence of events has\nbeen proposed to occur during the formation of tau inclusions\n(\n28, 29), what remains elusive is which PTMs actually drive\ntau self-association vs. those that are simply part of normal t au\nfunction and captured or trapped as “bystanders” in aggregates .\nThe transformation from healthy (functional) to aggregate d\n(or pathological) tau is most likely not a consequence of a\nsingle PTM, but rather a combination of the intrinsic structu ral\nalterations and extrinsic cellular conditions that may ult imately\nconstitute pathogenicity. Below, we describe the PTMs that ha ve\nbeen observed in tau and their potential impacts on tau functio n\nand dysfunction.\nPhosphorylation\nProtein phosphorylation is one of the most common PTMs\nin the proteome (\n30). Phosphorylation involves the reversible\naddition of a phosphate (PO 4) group to the polar group\nof serine, threonine or tyrosine amino acid residues ( 31)\n(Figure 2). Protein kinases and phosphatases, the enzymes\nresponsible for phosphorylation and dephosphorylation,\nrespectively (\n32), coordinate the phosphorylation status of\nproteins. Phosphorylation alters protein electrostatics by\nintroducing a negatively charged, hydrophilic group, resulti ng\nin an overall more hydrophilic protein. As a consequence\nof this increased hydrophilicity, phosphorylation imparts\nconformational changes, and regulates some important\nprotein functions including protein-protein interactions,\nsignaling cascades, and protein degradation (\n5, 33).\nPhosphorylation is involved in essential cellular functions\nsuch as metabolism and intracellular signaling, and therefo re, is\nfundamental to several normal cellular processes. However,\nabnormal phosphorylation has also been described as\none of the primary causes for the alteration of a variety\nFrontiers in Neurology | www.frontiersin.org 3 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\nFIGURE 2 | Relative frequency of post-translational modiﬁcations on t au. The\n2N4R isoform of tau contains 441 amino acid residues, around 35 percent of\nwhich can potentially undergo PTMs. These residues include serine (forty-ﬁve),\nthreonine (thirty-ﬁve), tyrosine (ﬁve), asparagine (three) , arginine (fourteen), and\nlysine (forty-four). The most common PTMs in tau are shown on the y-axis of\nthe bar plot. The x-axis of the plot shows the percentage of am ino acid\nresidues with solid bars showing the sites that have been ide ntiﬁed within total\npotential sites shown in shaded bars. The functional groups associated with\neach PTM are also shown next to each bar. Since all potential p hosphorylation\nsites have been identiﬁed, the shaded bar is completely maske d by the solid\nbar. Similarly, in case of N-glycosylation, the speciﬁc N-gl ycosylation sites have\nnot been reported and therefore, only potential sites repre sented by shaded\nbar have been shown.\nof structural, functional, and regulatory proteins under\ndisease conditions.\nThe longest isoform of tau, known as 2N4R tau, has 85\npotential phosphorylation sites (44 S, 35 T, and ﬁve Y) (\n34).\nTherefore, almost 20 percent of tau has the potential to become\nphosphorylated ( Figures 2, 3). Of these sites, ∼ 20 residues have\nbeen found to undergo phosphorylation in tau extracted from\nhealthy brains (\n35, 36). In contrast, around 44 residues, some of\nwhich overlap with residues found in tau from healthy brains ,\nhave been identiﬁed as “abnormally” hyperphosphorylated in\nindividuals with a tauopathy (\n25). Phosphorylation of serine and\nthreonine residues is associated with the completion of degro ns\n(or degradation-signaling motifs) and the subsequent clea rance\nof tau (for a more extensive discussion about phosphodegrons,\nsee section Eﬀect of PTMs on Tau Degradation). If tau\ndegradation is blocked, then these normally transient phospho -\nsites would persist, even though they are a part of the normal\nmetabolism of tau. Thus, the phosphorylation observed in tau\nextracted from diseased brains could either occur abnormal ly\nas part of disease pathogenicity or be a found as a normal\nevent to promote the normal, but interrupted, clearance of\ntau. Additionally, it is also possible that many other tau\nphosphorylation sites exist that have not been identiﬁed in pos t-\nmortem human brain material due to rapid dephosphorylation of\ntau (\n37).\nAs a dynamic and highly regulated process, tau\nphosphorylation requires a balanced interplay of kinases and\nphosphatases. Several serine/threonine kinases phosphorylate\ntau, including glycogen synthase kinase 3 (GSK3 β ), cyclin\ndependent kinase 5 (cdk5), casein kinase 1 (CK1), cyclic AMP-\ndependent protein kinase (PKA), p42/p44 MAPKs (ERKs 1/2),\nprotein kinase C (PKC), calmodulin-dependent protein kinase\nII (CaMKII), the brain-speciﬁc kinases 1 and 2, the tau-tubuli n\nkinases 1 and 2, and some microtubule aﬃnity-regulating kin ases\n(MARKs; also known as PAR1 kinases) (\n38). Furthermore, tau\ncan be phosphorylated by tyrosine kinases, such as the SRC\nfamily members (LCK, SYK, and FYN) and the ABL family\nmembers (ARG and ABL1) (\n39). FYN, SYK, and ABL kinases\nphosphorylate tau at the Y18, Y197, and Y394 residues ( 40),\nwhich have been associated with tau aggregation and AD\npathology (\n41).\nTau can be dephosphorylated by protein phosphatases (PP)\n1, 2A, 2B, 2C, and 5 ( 25). Among these phosphatases, PP2A\naccounts for around 70 percent of all tau dephosphorylation in\nthe human brain (\n42). Interestingly, PP2A also dephosphorylates\nand modulates the activity of components along the ERK1/2\nMAPK cascade that leads to GSK3 β activation (\n43), suggesting\npotential feedback cycles. As phosphorylation is one of the most\nstudied PTMs in tau, the kinase pathways implicated in tau\nphosphorylation have been extensively reviewed elsewhere (\n44).\nThe regulation of the phosphorylation status of tau is essenti al to\nmaintain the biological function of the protein.\nThe change in tau electrostatics associated with\nphosphorylation may have a critical role in the regulation\nof tau function, localization, and interaction with other\nmolecules. The phosphorylation status of tau is developmentall y\nregulated, implying the signiﬁcance of phosphorylation in the\nregulation of speciﬁc function of tau in each developmental\nstage (\n45, 46). Tau phosphorylation inside the microtubule-\nbinding domain (e.g., S262/S214) and/or the proline-rich (e .g.,\nT231) domain reduces the aﬃnity of tau for negatively charge d\nmicrotubules ( 47–50). Binding of tau stabilizes microtubules,\ntherefore tau phosphorylation regulates neuronal functions s uch\nas axonogenesis and neurite outgrowth ( 47, 51–53). Additionally,\nit has been reported that the speciﬁc phosphorylation of tau\nby FYN kinases induces the relocation of tau from the axon to\ndendrites (\n54). However, the eﬀects of tau relocation in neuronal\nfunction are not yet well-understood. Additionally, tau int eracts\nwith the kinesin-associated protein JIP1 (JUN N-terminal\nkinase-interacting protein 1) only when phosphorylated, there by\nimpairing the formation of the kinesin complex that mediates\naxonal transport (\n55).\nSince phosphorylation regulates the biological functions\nof tau, inappropriate phosphorylation may be an important\ncontributor to the pathogenesis of tauopathies. The abnormal\nphosphorylation in several residues inside the KXGS motif (\n25)\nand the proline-rich domain ( 47, 56–58) has been identiﬁed in\nNFTs of tauopathy patients brains. Aberrant tau phosphorylation\nat these motifs may pose detrimental consequences for neurons,\nsuch as the impairment of neurite outgrowth (\n59) and the\nderegulation of axonal transport ( 60, 61), which may lead\nto synaptic dysfunction and neurodegeneration ( 62–64). The\nphosphorylation at residues outside of the microtubules-bindi ng\nand proline-rich domains does not interfere with the ability o f tau\nFrontiers in Neurology | www.frontiersin.org 4 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\nFIGURE 3 | Tau undergoes diverse post-translational modiﬁcations tha t often compete for the same amino acid residues. Diagram sho wing the polypeptide chain of\nthe longest tau isoform 2N4R tau along with individual amino acid residues highlighting different regions/domains. The N-terminal inserts are represented with blue\nresidue borders, proline-rich domain is represented with p urple residue borders, microtubule-binding domains are re presented with green residue borders (R1, R3, R4\nin dark green, and R2 in light green), and disease-associate d amino acid variants are highlighted in red text. The vertic al black line between residues is shown for\ndistinction between two N-terminal inserts and four microt ubule-binding repeats. The colored dots represent the PTMs identiﬁed in tau (WT and mutant) in vitro and in\nvivo. The color code for PTMs is as follows: phosphorylation (lig ht blue), acetylation (pink), methylation (green), glycat ion (yellow), ubiquitination (red), O-GlcNAcylation\n(orange), SUMOylation (dark blue), and nitration (purple) . N-glycosylation is omitted as no speciﬁc sites have been ide ntiﬁed. The KXGS microtubule-binding motifs are\nshown in pink boxes. The canonical and potential KFERQ motif s are represented with dark blue and light blue boxes, respec tively. The phosphodegron motifs are\nhighlighted with green boxes.\nto bind microtubules. Some of these residues such as S396, S4 04,\nand S422, have been found abnormally “hyperphosphorylated”\nin diseased brains (\n57, 65), and it has been suggested that\nphosphorylation at these residues may inﬂuence tau aggregati on\n(66). While substantial published work suggests that tau\nphosphorylation may contribute to development of tauopathies,\nthe exact mechanism behind how phosphorylation regulates tau\nfunction and aggregation in vivo is still unknown. To unravel\nthe role of abnormal tau phosphorylation in tauopathies, it\nwill be necessary to better understand the broader impacts of\nphosphorylation on normal tau function.\nAcetylation\nThe acetylation of mammalian proteins involves the N-\nterminal addition of an acetyl group from acetyl coenzyme\nA (Ac-CoA) to the lysine residue of a polypeptide chain\n(\n67) ( Figure 2). Acetylation was ﬁrst described on histone\nproteins, therefore the associated enzymes are known as hist one\nacetyl transferases (HATs) and histone deacetylases (HDAC s),\nalthough they are less discriminating in their targets than\ntheir names would suggest (\n67). Acetylation is considered\nan essential modiﬁcation that plays critical roles in the\nfunction of diverse proteins, including p53 and tubulin (\n68).\nThe addition of an acetyl group neutralizes the positive\ncharge of lysine residues, thereby eliciting its downstream\nmolecular impacts on protein structure and protein-protein\nrecognition. Among its functional roles, acetylation is per haps\nbest known to regulate gene expression via modiﬁcation of\nhistone structure and chromatin accessibility (\n69). However,\nthe acetylation of non-histone proteins regulates a range of\ncellular processes such as DNA damage repair, cell division,\nsignal transduction, protein folding, autophagy, and metabo lism\nFrontiers in Neurology | www.frontiersin.org 5 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\n(70). Incorporation of an acetyl group onto lysine residues\nprevents other modiﬁcations and thus, acetylation also can\nblock the processes regulated by ubiquitination, SUMOylatio n,\nmethylation, and glycation.\nAcetylation has recently arisen to challenge the predominan ce\nof phosphorylation as the key PTM on tau. The longest isoform\nof tau protein (2N4R) contains 44 lysine residues and thus,\n10 percent of the protein has the potential to be modiﬁed by\nacetylation ( Figure 3). Among all HATs implicated in protein\nacetylation, p300 and its close homolog CREB-binding protein\n(CBP) appear competent to acetylate tau in vitro (\n71, 72).\nMoreover, the histone deacetylase 6 (HDAC6) ( 36, 73) and\nthe NAD + -dependent sirtuin 1 deacetylase (SIRT1) ( 72) are\nthe major tau deacetylases. Interestingly, these two HDACs\nhave seemingly opposing eﬀects on tau: while tau deacetylation\nby SIRT1 has a protective role against tau accumulation, the\ndeacetylation of tau by HDAC6 contributes to the increase\nof tau phosphorylation and aggregation in vitro (\n74, 75). Tau\nhas also been shown to undergo acetyl-coenzyme A–induced\nauto-acetylation in vitro (\n76). However, the role of tau as\nacetyltransferase remains somewhat controversial, given that\nother groups have not consistently identiﬁed tau acetylation in\nabsence of HAT enzymes ( 26, 76, 77).\nTau acetylation was ﬁrst recognized in the context of\nneurodegeneration in mouse models of neurodegenerative\ndisease (\n72, 78), and subsequently in brain lysates from AD\npatients at early/moderate Braak stages ( 79). The dysregulation\nof the HATs and HDACs involved in tau acetylation was also\nfound in diseased brains (\n79, 80). However, the underlying\nabnormalities of HAT and HDAC activity may be both context\nand disease speciﬁc. In this regard, while increased p300/CBP\nHAT activity was observed in the brains of FTLD-tau patients\n(\n80), p300/CBP levels, and activity were found to be lower in\nthe frontal cortex and hippocampus of AD patients ( 81) and\nin a mouse model of AD ( 82). Although these reports failed to\nshow the eﬀect of p300/CBP dysregulation in tau acetylation,\nthey suggest that the role of p300/CBP in tau acetylation may\nvary between diﬀerent tauopathies such as FTLD-Tau and AD.\nFurthermore, the levels and activity of HDACs have also been\nmeasured in patients’ brains. It has been observed that the\nexpression of SIRT1 is reduced in AD patients (\n83, 84) while\nthe levels of HDAC6 are increased ( 73), conﬁrming that these\nenzymes have opposite eﬀects on tau function and dysfunction.\nAltogether, this evidence demonstrates that tau acetylatio n may\nhave a key role in tauopathies.\nAs with phosphorylation, to fully understand the role of\nacetylation in tau dysfunction, one must necessarily under stand\nits role in the normal function of tau. While the neutralizat ion\nof positively charged lysine residues by acetylation appears\ncrucial for regulation of tau, the downstream functional im pacts\nof this regulation seem to be residue speciﬁc. For example,\nacetylation at lysine residue K280 weakens the binding of ta u\nto negatively charged microtubules, potentially destabili zing\nmicrotubule networks (\n26, 27, 85). This contrasts with acetylation\nat K174, which induces tau aggregation without aﬀecting\ntau-microtubule binding (\n79). Finally, HDAC6-regulated tau\nacetylation at KXGS motif-associated K259, K290, K321, or K 353\nresidues suppresses both tau phosphorylation and aggregation\n(\n36). Unlike acetylation of lysine residues that have been\nidentiﬁed only in tauopathy brains ( 26, 79, 86, 87), the acetylation\nat these four residues occurs in normal tau but is reduced in\ntauopathy brains (\n36). Since acetylation has emerged as a key\nPTM in the regulation of tau function and dysfunction, mapping\nall the acetylation sites on tau in diﬀerent biological contex ts\nwill help to delineate the ultimate roles and consequences of\neach modiﬁcation.\nAcetylation on tau is particularly interesting because many\nlysine residues that are targets for acetylation are also\ntargets for other PTMs, including ubiquitination, SUMOylatio n,\nmethylation, and glycation (\n78, 88, 89) ( Figure 3). Therefore, a\npotential rivalry between PTMs could exist, where the addition\nof one chemical group to a given residue blocks the addition\nof another, suggesting multilayered avenues for the regula tion\nof the biology of the protein (\n88). While the cross-talk between\nPTMs will be extensively discussed in section Cross-Talk and\nCompetition Between PTMs, below we review the role of other\nlysine-associated PTMs in tau function.\nUbiquitination\nCovalent modiﬁcation of proteins with ubiquitin (Ub)\n(ubiquitination or ubiquitylation) represents one of the\nmost common PTMs in mammalian cells ( Figure 2). The\nsmall, 76 residues, protein ubiquitin is nearly ubiquitousl y\nfound in eukaryotes (ergo its name) and is used to modify\nactivity, localization, or stability of other proteins (\n90, 91).\nUbiquitination involves a multi-step process carried out\nsequentially by activating (E1), conjugating (E2), and lig ating\n(E3) enzymes and has been reviewed elsewhere (\n92). Similar to\nacetylation, ubiquitination occurs on lysine residues. In ca se of\nubiquitination, the C-terminal carboxyl group of a lysine in the\nubiquitin sequence itself is covalently attached to the ε-amino\ngroup on a lysine of the “target” protein. Substrates can be\nmodiﬁed with a single ubiquitin (monoubiquitination) or wit h\npolymeric Ub chains of variable length (polyubiquitination) .\nThe ubiquitin protein contains seven lysine residues. Theref ore,\nthe nomenclature around ubiquitination is based upon which o f\nthese seven lysine residues serves as the initial link to the target\nprotein (i.e., ubiquitinated chains are called K6, K11, K27, K29,\nK33, K48, or K63) (\n93). The type of ubiquitin chain determines\nthe biological eﬀects of these modiﬁcations. Chains linked\nthrough K6, K27, and K33 are often involved in cell proliferati on,\nDNA damage repair, and innate immunity (\n91). Other linkages\nare directly related with protein degradation. In this regar d,\nK48 chains generally target substrates for degradation by th e\n26S proteasome ( 94), whereas K63-polyubiquitinated proteins\nare directed to the degradation by the autophagy-lysosomes\npathway (\n93–96).\nAs a protein rich in lysine residues, tau has a high\nsusceptibility toward ubiquitination. Out of a total of 44 ly sine\nresidues, 17 residues of the 2N4R tau isoform have been\nfound ubiquitinated with most of them located in the tau\nmicrotubule-binding domain (\n78, 97). The main role of tau\nubiquitination appears to be the regulation of tau clearance\nby the proteasomal or lysosome-autophagy systems (\n98). E3\nFrontiers in Neurology | www.frontiersin.org 6 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\nligases confer ubiquitin residues to target proteins ( 99). Among\n∼ 600 E3 ligases encoded by the human genome, only three\nappear competent to ubiquitinate tau: the C-terminus of the\nHsc70-interacting protein (CHIP), the TNF receptor-associa ted\nfactor 6 (TRAF6), and axotrophin/MARCH7 (\n100–102). Each\nof these E3 ligases ubiquitinates tau through diﬀerent linka ges\nand at diﬀerent residues, suggesting that each ligase modulat es\ntau degradation by diﬀerent mechanisms. CHIP ubiquitinates\ntau through K48 or K63 linkages and thus, regulates tau\ndegradation via both proteasomal and autophagy systems (\n102–\n104). On the other hand, the E3 ligase TRAF6 ubiquitinates\ntau via K63 linkages ( 100), suggesting that ubiquitination\nmediated by this enzyme may regulate the degradation of\ntau in the autophagy-lysosomes pathway only (\n100, 105–107).\nAdditionally, in vitro experiments have shown that tau can be\nmonoubiquitinated by axotrophin/MARCH7 ( 101). However,\nthe eﬀect of monoubiqutination by axotrophin/MARCH7 on tau\nfunction and degradation is not yet well-understood.\nWhile E3 ligases attach ubiquitins, deubiquitinases (dUbs )\nremove them. The cysteine protease Otub1 is the only dUb\nthat has been shown to target tau. Outb1 removes the K48\npolyubiquitin chains from endogenous tau, preventing tau\ndegradation in primary neurons derived from a transgenic\nmouse model (\n108) and thus implying an important role in the\nregulation of tau ubiquitination.\nUbiquitin has been found in aggregated tau extracted from\nthe brains of tauopathy patients. However, whether ubiquitin\nis causal, contributory, or simply a bystander in aggregatio n\nremains to be seen. Tau isolated from human AD brains has been\nshown to be monoubiquitinated at K254, K257, K311, and K317\n(\n109) and polyubiquitinated at K254, K311, and K353 residues\n(110). Tau was also found to be ubiquitinated at K290 in a mouse\nmodel of AD ( 78). Interestingly, insoluble tau from AD brains is\nmodiﬁed predominantly by K48 linkage ( 110), whereas soluble\ntau can also be ubiquitinated via K63 polyubiquitin conjugat ion\n(102), suggesting that soluble and aggregated tau are degraded\nby diﬀerent pathways. While ubiquitin is a component of tau\naggregates found in the brains AD patients (\n109, 111–113), tau\n“pre-tangles” did not exhibit positive ubiquitin immunostai ning\n(114–116). Moreover, it has been shown that tau phosphorylation\nprecedes ubiquitination in the NFTs of AD patients and that the\nformation of paired helical ﬁlaments precedes tau ubiquitina tion\nin vitro (\n109, 114), suggesting that ubiquitin may be linked\nto tau after the formation of the ﬁbrillar inclusions. This\nﬁnding potentially supports ubiquitination as a compensatory\nresponse to tau accumulation. In contrast, other groups have\nreported that both mono- and polyubiquitination contribute\nto the formation of insoluble protein inclusions present in\nneurodegenerative diseases (\n96, 117) and that the induction of tau\nubiquitination in cell cultures increases aggregation ( 102). The\nsomewhat contradictory nature of the current literature ar ound\nubiquitination suggests that whether this modiﬁcation is c ausal,\nconsequential, bystander, or context speciﬁc in disease rem ains to\nbe sorted.\nSUMOylation\nIn SUMOylation, the small ubiquitin-like modiﬁer protein\nSUMO is transferred to the terminal amino group of lysine side\nchains of the target protein by an ATP-dependent enzymatic\ncascade. Analogous to ubiquitination, this SUMOylation cas cade\ninvolves an E1 activating enzyme, an E2 conjugating enzyme,\nand an E3-type ligase ( Figure 2) (\n118, 119). SUMO groups\ncan be removed by speciﬁc proteases known as SUMO-speciﬁc\nproteases/isopeptidases (SENPs). Three main SUMO isoforms\nare expressed in cells: SUMO1, SUMO2, and SUMO3, of which\nSUMO2 and SUMO3 are more similar to each other and are\ndiﬀerent from SUMO1 (\n120).\nSUMO is predominantly found in the nucleus and thus,\nSUMOylation plays a crucial role in many nuclear processes\nsuch as gene expression, genome stability (\n121), DNA damage\nresponse ( 122), protein traﬃcking ( 123), and cell cycle control\n(124). SUMOylation has emerged as an essential regulator\nof neuronal function with a growing evidence suggesting\nthat SUMOylation of proteins inside and outside the nucleus\nplays an important role in neurodegenerative diseases (\n125).\nAlterations in protein SUMOylation are observed in a wide\nrange of neurological and neurodegenerative diseases inclu ding\ntauopathies (\n126–128), and several extranuclear disease-\nassociated proteins including tau have been shown to be direc tly\nSUMOylated (125).\nIn vitro studies have demonstrated that tau can be\nSUMOylated. Speciﬁcally, it has been found that tau is\nmonoSUMOylated in vitro at the K340 residue, which is\nlocated within the microtubule-binding domain (\n128, 129).\nTau becomes available for SUMOylation only after it is releas ed\nfrom microtubules ( 129), suggesting that SUMOylation may\nbe a secondary PTM that occurs after phosphorylation and/or\nacetylation. However, little is known about how SUMOylation\ninterferes with the formation of tau inclusions in tauopathi es.\nTau SUMOylation at K340 inhibits tau ubiquitination and the\nsubsequent proteasome-dependent degradation, suggesting t hat\nSUMOylation may block tau degradation and therefore induces\ntau accumulation and aggregation (\n128). In contrast, previous\nevidence indicates that the inhibition of the proteasome path way\nstimulates tau ubiquitination and eliminates tau SUMOylati on\n(129), suggesting that SUMOylated tau can be degraded by\nother pathways such as autophagy. In this context, a more\nrecent study has demonstrated that SUMO1 labels lysosomes in\noligodendrocytes from PSP patients containing tau inclusio ns\n(\n127), an indicator that SUMOylation may be regulating\nautophagy-lysosomes pathway in tauopathies. Additionally, the\nactivation of autophagy-lysosomes pathway appears to reduce\ntau SUMOylation, tau inclusions and cortical atrophy associa ted\nwith the rTg4510 mouse model of tauopathy (\n130). Despite\nthe role of SUMOylation in tau function and dysfunction not\nbeing completely understood, substantive evidence support\nSUMOylation competing with ubiquitin for lysine residues in\ntau, with consequences on tau clearance in the proteasome\nand/or autophagy-lysosomes systems.\nFrontiers in Neurology | www.frontiersin.org 7 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\nMethylation\nMethylation is a biochemical process that involves the transf er\na methyl group (CH 3) to DNA or protein targets ( Figure 2).\nDNA methylation was discovered contemporaneously with the\ndiscovery of DNA as genetic material (\n131, 132). On DNA,\nmethylation is regarded as an epigenetic means of regulating\ngene expression through blocking transcription factor bindi ng or\nrecruiting transcriptional repressors (\n133). Protein methylation\nwas ﬁrst described in histones. This was followed by decades\nof limited interest until the physiological role for protein\nmethylation was documented in the late 1990s and non-histon e\nproteins were also found to be methylated (\n134). Currently,\nmethylation is fourth on the list of PTMs in terms of overall\nabundance in the proteome, with more than 18,000 methylation\nsites described in ∼ 7,400 proteins (\n135). The N-methylation of\nhistone and non-histone proteins occurs primarily on lysine an d\narginine residues. In the process of DNA or protein methylatio n,\nmethyl groups from an S-adenosyl methionine (SAM) donor are\nconferred by methyltransferases and removed by demethylas es\n(\n136). Lysine residues can be methylated up to three times,\nresulting in a mono-, di-, or trimethyl-lysine, which each g ive\nrise to distinctive biological consequences. Indeed, alth ough\nthe methyl group is one of the smallest post-translational\nmodiﬁcations, each methylation event removes a proton from\nthe ε-amino group and thereby decreases the hydrogen-bonding\npotential of lysine. Therefore, methylation also increases the\nhydrophobicity and bulkiness of lysine side-chains. Based o n the\nelectrostatic properties of methylation, this PTM has been sh own\nto regulate diﬀerent aspects of proteins function such as protei n–\nprotein and protein–nucleic acid interactions, protein stabi lity,\nsubcellular localization, and enzyme activity, which in tu rn\naﬀect essential cellular processes including transcription, protein\nsynthesis, signal transduction, and metabolism (\n137, 138).\nTau methylation is a relatively recent discovery ( 89). Results\nfrom mass spectrometric analyses show that several lysine\nresidues are methylated on tau extracted from either health y\nindividuals or AD patient brains (\n89, 139–141). Moreover,\nin mouse models tau is also methylated at arginine residues\nR126, R155, and R349 (\n78). The number of methyl residues in\ntau protein is relatively low compared to other modiﬁcations\nsuch as phosphorylation and acetylation (\n140). Tau from\nboth healthy and AD patient brains can be mono and\ndimethylated (\n141, 142). Interestingly the methylation status of\ntau changes qualitatively with aging and disease progressio n\n(89, 140, 143). Inherent in this ﬁnding is the possibility\nthat aging alone, rather than disease per se , dictates tau\nmethylation, analogous to the “Aging Clock” described for D NA\nmethylation (144).\nUntil now, the speciﬁc enzymes involved in tau methylation\nhave not been identiﬁed, and the exact role of methylation\nin tau function and pathogenesis is unclear. Methylation\nchanges the electrostatics of tau protein. Given that tau is\nmethylated within the KXGS motifs, regions that are essenti al\nfor interactions with microtubules, lysine methylation ma y\nsuppress tau’s microtubule-binding function (\n139). Since tau\naggregates from AD patients are methylated ( 89), it has also been\nsuggested that methyl residues can bind to tau after aggrega tion\nand perhaps impair ubiquitination and UPS-mediated\ndegradation (\n89). Future investigation of site-dependent\ntau methylation in vivo , and determination of its relationship\nto the DNA methylation “Aging Clock”, would advance our\nunderstanding of the role of this modiﬁcation in tau functio n\nand pathology.\nGlycosylation and Glycation\nGlycosylation involves the addition of carbohydrate chain s to\nproteins and lipids, of which we will focus on the former. Prote in\nglycosylation is classiﬁed into two subtypes depending on the\ntype of reaction involved: enzymatic glycosylation and non-\nenzymatic glycosylation (aka glycation). Enzymatic glycosy lation\ntypically occurs on secreted proteins or those that remain\nin membrane-bound organelles, hence this process occurs in\nthe endoplasmatic reticulum (ER)/Golgi system. In addition,\na specialized enzymatic glycosylation called O-GlcNAcylat ion\noccurs almost exclusively on cytoplasmic and nuclear (non-\nsecreted) proteins (\n145). Given that the addition of sugar\ngroups has steric eﬀects on proteins, both enzymatic and non-\nenzymatic glycation have been described to play a major role\nin determining the structure and stability of proteins (\n146).\nHowever, while enzymatic glycosylation is an important PTM\nthat exerts functional eﬀects on glycoproteins, glycation typica lly\nresults in dysfunctional or defective biomolecules (\n146, 147).\nBoth enzymatic and non-enzymatic glycosylation of tau funct ion\nare discussed below.\nEnzymatic Glycosylation\nEnzymatic glycosylation is a process in which glycosyltransf erase\nenzymes attach activated sugar donor groups (monosaccharid es)\nto proteins via covalent, glycosidic linkages (\n148–150). Sugar\ngroups are linked to either asparagine (N-glycosylation) or\nserine/threonine (O-glycosylation) residues ( Figure 2) (\n146). N-\nglycosylation begins as a co-translational event in the ER.\nThere, the oligosaccharyltransferase enzyme adds an immatu re\npolysaccharide to a nascent polypeptide chain. After the furthe r\nmaturation of this polysaccharide, the resulting glycoprotei n\nis transferred to the Golgi apparatus, where the sugar groups\nacquire an even more complex structure during a process called\n“terminal glycosylation” (\n149). Conversely, O-glycosylation is\nachieved post-translationally in the cis-Golgi compartment ( 151).\nN- and O-glycosylation also diﬀer in the linker-residue of\nthe targeted protein. N-glycosylation is characterized by th e\nenzymatic addition of N-glycans to asparagine residues in th e\nsequence N-X-S/T (where X is any amino acid except P or D),\nbeing X any amino acid except proline (\n149). O-glycosylation\noccurs on S/T residues with a β -turn in the proximity of a\nproline residue, however the O-glycosylation domains are not\nexactly deﬁned (\n152). Both N- and O-glycosylation impact the\nstructure, stability, folding, oligomerization, and solu bility of\nglycoproteins (143, 153, 154).\nSome proteins can additionally undergo a specialized and\nhighly dynamic form of O-glycosylation called O-GlcNAcyla tion\nor O-GlcNAc. O-GlcNAcylation diﬀers from other types of\nglycosylation in that the glycan is not further processed afte r\nthe addition of a single GlcNAc to S/T residues. It also occurs\nFrontiers in Neurology | www.frontiersin.org 8 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\nalmost exclusively on intracellular (nuclear and cytoplasm ic)\nrather than secreted proteins ( 151). O-GlcNAcylation is highly\nregulated by two enzymes, O-GlcNAc transferase (OGT) and\nO-GlcNAcase (OGA) that add and remove sugar groups,\nrespectively (\n145). Because O-GlcNAcylation aﬀects S/T residues,\nmany known O-GlcNAcylation sites are nearby or overlapping\nwith phosphorylation sites and thus it has been suggested that\nthese two post-translational modiﬁcations can regulate eac h\nother (\n145, 155–159).\nEnzymatic glycosylation may contribute to tauopathies by\nmodifying proteins other than tau, such as APP and the β -\nsite APP-cleaving enzyme 1 (BACE1). APP and BACE1 have\nbeen found to be O-glycosylated (\n160–162) and N-glycosylated\n(163, 164) in tauopathy patients’ brains. Tau also has the potential\nto be modiﬁed by N-glycosylation and by the specialized form\nof O-glycosylation, O-GlcNAcylation (\n165, 166). Interestingly,\nto date tau has been found to be N-glycosylated only in AD\nsubjects (\n167–169), while O-GlcNAcylation levels are relatively\nelevated in brains from normal controls ( 155, 166, 170). To date,\nat least ﬁve O-GlcNAc sites have been mapped in tau (T123, S208,\nS238, S400, and one of S409/412/413) (\n171–173) and all of them\nare also susceptible to phosphorylation. Therefore, it has bee n\nspeculated that O-glycosylation may compete with or protect\nfrom phosphorylation (\n155, 174). Since tau O-GlcNAcylation is\ndecreased in diseased brain ( 155, 170), it has been suggested that\nthis PTMs has a protective role. This hypothesis is potentially\nsupported by the fact that that O-GlcNAcylation increases\nthe interaction of tau with microtubules (\n175), increases tau\ndegradation ( 166), and suppresses tau aggregation ( 171, 175,\n176).\nDespite tau being N-glycosylated, the exact residues have no t\nbeen identiﬁed. Furthermore, the relevance of N-glycosylat ion\nin tau function is a matter of debate since tau is a cytosolic\nprotein, but the N-glycosylation process occurs in the ER-Gol gi\nsystem (\n177). Therefore, tau N-glycosylation is thought to be\nassociated with aberrant subcellular localization of tau. However,\nthe mechanisms and consequences behind tau relocation are s till\nelusive. It has been proposed that N-glycosylation precedes and\naccelerates tau phosphorylation (\n169), either by suppressing tau\ndephosphorylation ( 178) and/or inducing tau phosphorylation\nby protein kinase A (PKA) ( 169, 178). While a direct impact\nof tau N-glycosylation on microtubule polymerization and\nstability has not been observed (\n167), the removal of N-\nglycans and phosphate groups of tau seems to restore its\nmicrotubule polymerization activity (\n164). Although little is\nknown about the role of N-glycosylation in tau biology, this\nevidence suggests that aberrant N-glycosylation of tau may b e\ninvolved in neurodegenerative disease pathogenesis.\nGlycation or Non-enzymatic Glycosylation\nGlycation (or non-enzymatic glycosylation) is a PTM in whic h\nsugars or sugar-derived metabolites are covalently attache d to\nthe side chain of lysine residues ( Figure 2). The glycation\nprocess involves a set of chemically heterogeneous modiﬁcat ions\nthat lead to the formation of advanced glycation end-product s\n(AGEs) (\n179). AGEs are produced by the irreversible cross-link\nbetween glycated and non-glycated proteins and are consider ed\nglycotoxins with signiﬁcance in aging and age-related disea ses\n(180–182). Both early stage glycation and AGEs have been shown\nto impair protein activity. Moreover, AGEs deposition has been\nshown to correlate with age and disease progression in AD (\n183).\nAlthough the study of AGEs is an active area of investigation in\nthe ﬁeld of aging research ( 184), it is still unknown how proteins\nare selected to be glycated and the biological role of glycati on in\nneurodegeneration is not well-understood ( 185).\nThirty-two lysine residues in 2N4R tau have been identiﬁed in\nvitro as potential glycation sites ( 186, 187) ( Figure 3). Although\nmost of these sites were detected in both 3R and 4R isoforms,\nK280 and K281 are absent in the 3R tau, and this diﬀerence\nseems suﬃcient to slow the glycation of 3R relative to 4R isofo rms\n(\n186, 187). In AD, glycation has been detected in aggregated tau\npuriﬁed from human AD brains but not in soluble tau ( 188).\nThe molecular functions for glycation, the sites of these rea ctions\nand whether or how they contribute to tau aggregation remain\nsubjects for debate. Since the glycation of tau in microtubul e\nbinding domains reduces tau aﬃnity for microtubules in vitro\n(\n189), it has been suggested that glycation sterically blocks\ntau-microtubule interactions. Glycation may also induce the\naccumulation of tau by blocking the ubiquitination of tau at\nlysine residues and consequently its degradation (\n189, 190).\nFurthermore, the late glycosylation product known as AGEs ha ve\nalso been found colocalized with pathological tau aggregate s in\nthe brain of sporadic AD cases ( 191). Similarly, AGEs colocalize\nwith NFTs from PSP , PiD, and ALS patients ( 180, 191). Although,\nthe role of glycosylation in tau function is not well-underst ood,\nevidence presented here implies that this PTM can play an\nimportant role in tauopathies.\nProteolysis\nProteolysis refers to the breakdown of proteins into peptides a nd\namino acids through the hydrolysis of peptide bonds via the\naction of proteases. Most proteases are highly speciﬁc and cleave\ntheir protein substrates from the N-terminus (aminopeptidase s),\nC-terminus (carboxypeptidases), or more centralized region s\n(endopeptidases) of a protein. Furthermore, based on their\ncatalytic mechanisms for substrate hydrolysis and the resid ues\nassociated with their active sites, proteases are categoriz ed into six\ntypes: aspartyl, cysteine, glutamic, metallo, serine, and thr eonine\nproteases. Proteolysis is a critical modiﬁcation that can le ad to\nalterations in protein function with important outcomes in ma ny\nbiological processes including signaling pathways and apoptosi s.\nIt can regulate the concentration of a protein, transform a\nprotein into an active form, or process a protein to provide the\namino acids required to synthesize a diﬀerent protein. Proteo lysis\nalso plays an important function in removing damaged or\nunnecessary proteins from cells.\nSeveral cytosolic proteases responsible for tau proteolysis\nhave been identiﬁed, including caspases, calpains, and throm bin\n(\n192). Caspases are a family of evolutionarily conserved cysteine-\ndependent proteases that cleave proteins after speciﬁc aspartic\nacid residues (\n193). These proteases play a crucial role in\nimportant biological process such as apoptosis and inﬂammation\n(\n194). Thirteen diﬀerent caspases have been described in humans,\nand their functional classiﬁcation is reviewed elsewhere ( 193).\nFrontiers in Neurology | www.frontiersin.org 9 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\nThe role of proteolysis in tau function is incompletely\nunderstood. Tau proteolysis could be protective and may\npromote the removal of abnormal tau or could favor the\nabnormal accumulation of cleaved tau in the cell (\n195). It is also\npossible that tau cleavage is neither protective nor damaging ,\nbut is merely a bystander eﬀect of tau accumulation. The\nproteolytic cleavage of tau has been observed both in vitro\nand in vivo (\n192, 195). Prior research on tau proteolysis has\nalso shown that the proteolytic cleavage of tau precedes its\naggregation in vitro (\n196–198). Furthermore, the N-terminal\ntruncation of tau has been shown to alter the cellular\nlocalization of the protein from the cytosol to the nucleus\n(\n199), indicating a possible link between proteolysis and tau\nlocalization. Given that it has been shown that tau fragment s\ninduce death in cultured neurons ( 200), it has been suggested\nthat tau cleavage may induce neurodegeneration. However, t he\ntoxic nature of tau fragments has not been demonstrated in\nvivo and therefore, it remains unclear if these fragments are\nindeed toxic.\nThe in vitro cleavage of tau by caspase-3, − 7,− 8, and less\neﬃciently by caspases-1, and − 6 resulting in the formation of\nan N-terminal fragment, tau1-421 (Tau-C3) ( 198, 201, 202)\nhas been demonstrated. Tau-C3 fragment has been observed\nin AD brains (\n198) and interestingly, the active forms of both\ncaspase-3 and caspase-6 are elevated in AD brains compared to\ncontrol brains (\n203–205). While the exact function of Tau-C3\nfragment is unknown, it has been shown that Tau-C3 fragment\ninduce toxicity in neuronal cultures (\n201, 206, 207), and that\nthe caspase-mediated tau cleavage precedes tangle formation in\ntau transgenic mice (Tg4510) ( 208). However, whether caspase-\nmediated cleavage of tau is toxic or protective for the neuron s still\nremains a matter of debate.\nWhile the proteolytic cleavage of tau by caspases has\nbeen extensively studied, the cleavage of tau by calpains\nand thrombin remains elusive. Calpains are calcium-activat ed\ncytosolic cysteine proteases implicated in a variety of calci um\nassociated cellular functions like cell proliferation, migr ation,\ninvasion, apoptosis, and signal transduction (\n209). Dysregulation\nof calcium homeostasis has been proposed to induce abnormal\nactivation of calpains in a number of neurodegenerative dise ases\n(\n209). The cleavage of tau by calpains, has been demonstrated\nin vitro and in neuronal cultures ( 210, 211). According to a\nrecent study, calpain-mediated cleavage events are conside red a\npart of normal tau protein processing ( 212). However, there are\nstudies that have suggested that calpain-mediated proteolys is of\ntau may induce toxicity, as seen in cell cultures and a Drosophila\ntauopathy model ( 210, 213). Thrombin is a cytosolic serine\nprotease that is expressed within neurons and astrocytes ( 195).\nThe cleavage of tau by thrombin has been shown in vitro and in\ncell models of tauopathy ( 214, 215). Based on cell culture-based\nstudies, thrombin cleavage products of tau are believed to be\npotentially pathogenic (\n216, 217). However, due to contradictory\nreports and lack of in vivo evidence for tau proteolysis mediated\nby these enzymes, the relevance of thrombin, and calpains in t au\nfunction remains unclear. Naturally, tau cleavage also occ urs in\nthe proteasome and lysosomes, which will be discussed furthe r in\nsection Eﬀect of PTMs on Tau Degradation.\nOther PTMs\nIn addition to the PTMs discussed above, several other post-\ntranslational modiﬁcations occur on tau, which are less well -\nrecognized. Below, we discuss three diﬀerent tau PTMs that fal l\nin this category: protonation, oxidation, and nitration.\nProtonation\nProtonation involves enzyme-independent, rapid, and revers ible\naddition or removal of protons. Protonation adds a positive\ncharge to otherwise uncharged amino acid side chains and\ntherefore can lead to dynamic changes in protein conformatio n\nand function (\n218). The optimum protonation state of a protein\nis critical to its functioning. Dysregulation in local pH can l ead to\ndisruption in the protonation state of a protein and has recentl y\nbeen shown to have implications with neurodegenerative disea ses\n(219, 220). Among several protein sites that can participate in the\nprotonation/deprotonation process, only a few can signiﬁcant ly\nundergo this modiﬁcation within the normal cytosolic pH rang e.\nHistidine side chains, with a nominal pKa of ∼ 6.5, are among\nthe most attractive residues for protonation within cytosol ic\npH range.\nTau contains highly-conserved histidine residues near the\nC-terminus of each microtubule-binding tau repeat ( Figure 3)\n(221). These residues have been proposed to act as pH\nsensors and inﬂuence tau–microtubule interaction within t he\nphysiological intracellular pH range ( 221). The histidines are\npositively charged at pH <7.5 and show increased tau-\nmicrotubule binding ( 221). However, at pH >7.5, histidine\nresidues in tau are deprotonated and bind microtubules with\nlower aﬃnity (\n221). Furthermore, it has been proposed that\na highly conserved histidine residue, H299 ( Figure 3), near\nthe R2 C-terminus seems to contribute to tau–microtubule\nbinding. The labile nature and minimal molecular weight cha nge\nof protonation renders it diﬃcult to detect by traditional\napproaches, such as mass spectroscopy or gel electrophoresis,\nused to detect PTMs. Nonetheless, given its eﬀects on protein\nstructure, solubility and function, protonation should be\nconsidered as a post-translational protein modiﬁcation like the\nothers in this review.\nOxidation\nLike protonation, protein conformation is also sensitive to\noxidation-reduction (redox) changes. Redox homeostasis is\nachieved by the regulation of appropriate levels of reactive\noxygen (ROS) and nitrogen (RNS) species, that are considered\nimportant physiological regulators of intracellular signali ng\npathways (\n222). The dysregulation of ROS is a major contributor\nto oxidative damage and it has been proposed that age-related\naccumulation of oxidized proteins may contribute to the agin g\nprocess (\n223). However, the importance of protein oxidation\nin the progression of aging still remains poorly understood.\nCysteine residues are the prime amino acid that can exist in\noxidized or reduced states. The unique properties of cysteine\nside chain allows it to undergo various oxidative PTMs, which\ncan potentially have diverse regulatory eﬀects. The oxidatio n of\ncysteine residues leading to disulﬁde bond formation is one o f the\nFrontiers in Neurology | www.frontiersin.org 10 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\nwell-established mechanisms underlying the redox regulat ion of\nprotein conformation and hence its function.\nOn tau, there exists a pair of cysteine residues that can\nundergo oxidation ( Figure 3). While the eﬀect of oxidation on\ntau function is unknown, its role in tau aggregation has been\nstudied in vitro (\n224) and is discussed in section Eﬀect of PTMs\non Tau Solubility and Aggregation of this review. Tau oxidat ion\nhas only been described in vitro , and therefore the status of\noxidized tau in vivo remains unclear.\nNitration\nNitration involves the addition of nitrogen dioxide (NO 2) onto\ntyrosine residues. The mechanism underlying protein nitrat ion is\nnot clear but it most likely involves the presence of ROS/RNS-\nlike peroxynitrite and therefore nitration can also occur du ring\noxidative damage (\n225). Several lines of evidence suggest a role of\nnitration in physiological processes like signal transducti on (226,\n227). Additionally, increased protein nitration has been ident iﬁed\nin a large variety of diseases and have also been implicated in the\nprocess of aging ( 227).\nThe 2N4R tau isoform has ﬁve tyrosine residues, and the\nnitration at four of them has been shown in vitro : Y-18, Y-\n29, Y-197, and Y-394 ( Figure 3). These studies have shown that\nresidues Y-18 and T-29 are more susceptible toward nitration\nthan residues Y-197 and Y-394. The nitration of tau at Y-\n197 has been observed in the healthy brain and therefore has\nbeen proposed to have important physiological functions (\n228).\nHowever, the nitration of Y-18, Y-29, and Y-394 has only been\nobserved in AD or other tauopathies (\n229). It is believed that\nnitration of these tyrosine residues alters tau conformati on and\nreduces its ability to bind to microtubules ( 230). While there are\nsome interesting insights on tau nitration, most of these st udies\nare based on in vitro experiments. Therefore, studies focusing on\nthis PTM will provide additional useful insights into its rol e in\ntau pathobiology.\nEFFECT OF PTMs ON TAU DEGRADATION\nProtein degradation is important for the maintenance of\nproteostasis and for preventing the accumulation of misfolde d\nor aggregated protein species (\n231). There are two major\nprotein degradation systems in the cell: the ubiquitin-prote asome\nsystem (UPS) and the autophagy-lysosomes pathway ( 231).\nBoth protein degradation pathways are key eﬀectors of the\nproteostasis network and are strongly inﬂuenced by PTMs.\nProtein clearance is highly regulated and utilizes ubiquit in\nas a tag for direct protein degradation in both proteasomal\nand autophagy systems. However, other PTMs also aﬀect the\nprocess of protein degradation indirectly. This is the case fo r\nphosphorylation and acetylation, both of which can modify\namino acid sequences known as degrons, which are important\nfor protein degradation.\nA subset of degrons are regulated by phosphorylation and\nthus are called phosphodegrons (\n232, 233). Phosphodegrons\nare short linear amino acid sequences, D/E-S/T- GXX-S/T-P or\nLL-S/T-PXX-S/T-P , where the phosphorylation of S/T residues\npromotes protein clearance through stimulation of subsequen t\nubiquitination and proteasomal degradation ( 232, 233). Proteins\ncan also contain other motifs that promote degradation by\nthe autophagy-lysosomes system. These pentapeptide motifs\nare known as KFERQ motifs as they are composed of\none or two positively charged residues (K, R), one or two\nhydrophobic residues (I, L, V , F), one negatively charged\nresidue (D, E), and one bookending glutamine (Q) (\n234).\n“Canonical” KFERQ motifs are complete without modiﬁcation\nwhile “potential” KFERQ motifs require completion via a\nPTM such as phosphorylation (\n235) or acetylation ( 234, 236)\n(Figure 3).\nTau homeostasis is typically maintained via degradation by\nboth UPS and autophagy-lysosome systems ( 96, 110). Yet at some\npoint in the pathobiology of tauopathies, the local concentrat ion\nof tau must increase to favor the formation of ﬁbrils, oligom ers,\nand aggregates. Does self-association of potentially abnorm ally\nmodiﬁed tau lead to damage and subsequent impairment of\nprotein degradation systems? In this model, tau accumulation\nis causal for neurodegenerative disease. Or, alternatively , does\ntau accumulation result from decreased eﬃciency or failure of\nthe protein degradation systems? In this case, tau accumulati on\nis a consequence of other pathobiology in neurodegeneration .\nThis type of binary, chicken, or egg approach to the genesis of\ntauopathies may be over-simpliﬁcations of a complex, biologic al\nmilieu that combines aspects of both tau accumulation as caus e\nand consequence. Nonetheless, the answers to these question s are\nkey, as they dictate certain nodes to target for disease thera py. In\nthis section, we will delineate the pathways for tau clearance an d\ndescribe how PTMs could play active roles in these processes.\nTau Clearance by the\nUbiquitin-Proteasome Pathway\nThe UPS pathway is responsible for the clearance of soluble,\nintracellular proteins (\n237, 238). The proteasome is a highly\norganized and complex molecular machinery responsible for\nthe selective and eﬃcient degradation of client proteins, whose\nbasic science and function has been reviewed elsewhere (\n239–\n242). The 26S proteasome is responsible for the majority of\nprotein clearance in mammalian cells and degrades proteins\nthat are tagged with polyubiquitin chains (\n195). Therefore,\nthe fact that tau is a target of ubiquitination (as discussed\nabove) (\n109, 110) suggests that it can be degraded by\nthe proteasome.\nWhile ubiquitination is the proximal signal for protein\ndegradation in the UPS, other PTMs such as phosphorylation are\noften required for tau ubiquitination to occur (\n243). For example,\ntau phosphorylated at proline-directed serine/threonine site s\nis selectively ubiquitinated by CHIP ( 103, 243), and thus\nphosphorylation in these sites increases tau ubiquitination\nand UPS-mediated degradation. Given that tau has six\nphosphodegron sequences ( Figure 3), phosphorylation also\nregulates the ubiquitination and degradation of tau throug h this\nmeans (\n233). Phosphorylation of tau degrons is highly regulated\nby diﬀerent kinases such as cdk5 and GSK3 β (244), which work\ntogether in order to phosphorylate tau at speciﬁc residues and\nprepare the molecule for ubiquitination and degradation (\n245).\nFrontiers in Neurology | www.frontiersin.org 11 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\nHowever, phosphorylation of tau at alternative sites prevents\nubiquitination and clearance. As a case in point, phosphorylati on\nof tau at the KXGS motifs in the C-terminal microtubule\nbinding repeat domains seems to prevent the ubiquitination an d\ndegradation of tau (\n243).\nThe dysfunction of the UPS and its related PTMs are\nassociated with the development of tauopathies. Insoluble ta u\naggregates isolated from human AD brains contain proteasome\nsubunits (\n246). Ubiquitin ligases such as CHIP and TRAF6 also\ncolocalize with tau in AD brains ( 102, 103). Ubiquitinated tau\nis a component of NFTs ( 246). Further, a recent study from our\ngroup showed that the PSP-related A152T tau variant increases\ntau phosphorylation at threonine 153, potentially interferin g\nwith recognition of the local phosphodegron and thereby UPS\ndegradation (\n233). Impairment of UPS activity has also been\nobserved in postmortem human AD brains ( 246–250). While\ntogether these data implicate the UPS in tauopathies, they\nnonetheless represent correlative, rather than causal evid ence.\nTo our knowledge, no studies have established UPS failure\nas necessary and suﬃcient in promoting tau accumulation,\naggregation, neuronal loss, and neurodegeneration.\nTau Clearance by Autophagy\nAutophagy is the process by which unnecessary or damaged\ncellular components are proteolytically degraded in the\nendosomal-lysosomal pathway. Based on the mechanisms\nby which the substrate is delivered for degradation, there\nare three major types of autophagy: chaperone-mediated\nautophagy (CMA), endosomal microautophagy (e-MI), and\nmacroautophagy. Long-lived proteins or protein aggregates\nthat are too large to be processed through the proteasome are\ntypically degraded via autophagy (\n242). Tau, being a long-lived\nprotein, is anticipated to be degraded in lysosomes ( 242) and\nindeed, it has been shown that both soluble and insoluble tau\ncan be degraded by the three forms of autophagy (\n251, 252).\nFurthermore, it has been observed that the use of autophagy\ninhibitors, such as ammonium chloride (NH 4Cl), chloroquine,\nand 3-methyladenine (3-MA), as well as the inhibition of\nlysosomal proteases, delays tau clearance, and enhances\ntau accumulation (\n253–255), conﬁrming the importance of\nautophagy in tau degradation.\nNot only is tau cleared by autophagy, but PTMs play\ndistinct roles in modulating these processes. Within the ami no\nacid sequence of the tau protein are found two KFERQ\nmotifs ( 336QVEVK340 and 347KDRVQ351) ( Figure 3). These\nconsensus sequences direct tau toward either chaperone-\nmediated autophagy or endosomal-microautophagy (\n252, 256).\nIn addition to the two canonical KFERQ motifs, tau contains\nfour potential KFERQ motifs that can become canonical in the\npresence of phosphorylation, acetylation, or a combination of\nboth ( Figure 3) ( KFERQ ﬁnder) (\n234), emphasizing that PTMs\nplay an important role in the degradation of tau by these\ntwo systems. CMA-mediated protein degradation is a selective\nform of protein clearance in which the KFERQ motifs are\nrecognized by the Hsc70 chaperone. Upon recognition, the\nproteins are transported to the lysosomal lumen after binding to\nthe lysosome-associated membrane protein-2 (LAMP-2) (\n257).\nTau protein can be eﬃciently degraded by CMA as long as the\nKFERQ motifs are not blocked by PTMs (\n252).\nIn addition to initiating CMA, the binding of Hsc70 to\nKFERQ motifs also targets cytosolic proteins for selective\ndegradation by e-MI. This form of protein degradation occurs\nin late endosomes/multivesicular bodies instead of lysosome s\nand involves sequestering substrate proteins into intralum inal\nvesicles budding in toward the lumen of multivesicular\nendosomes (\n234, 256). Unlike CMA, in mammals, the presence\nof KFERQ motifs is necessary but not suﬃcient for e-MI ( 256).\nIn addition to protein cargo delivery by Hsc70, the e-MI pathway\nrelies on the ESCRT (endosomal sorting complexes required\nfor transport) I and III complexes that are required for the\nformation of vesicles which internalizes the cytosolic carg o (\n256).\nA recent study has analyzed the inﬂuence of two diﬀerent\nPTMs, oxidation and phosphorylation, on the e-MI-dependent\ndegradation of tau (\n251). A substantial decrease in the association\nand internalization of tau in late endosomes via e-MI was\nobserved upon oxidation of mutant tau, which suggests that th e\noxidation of tau at C291/C322 is a prerequisite for completing\nthe internalization of tau through e-MI (\n251). Moreover, in\nthe same study, the authors found that phosphorylating tau at\nS262, S293, S324, and S356 inside microtubule-binding doma ins\ndiminishes its degradation by e-MI (\n251). In contrast, another\nstudy showed e-MI mediated degradation of total tau and of\nspeciﬁc phosphorylated species (\n258). Thus, PTMs regulate the\nclearance of tau degradation by both CMA and e-MI.\nNon-soluble, larger or aggregated species of tau are cleared\nvia macroautophagy, a form of autophagy that involves the\nsequestration of cytoplasmic cargo into double-membrane\nvesicles known as autophagosomes, which fuse with the lysosome\nto degrade its contents (\n259). Several reports have conﬁrmed\nthat tau aggregates can be degraded by macroautophagy. For\nexample, the aggregates generated by the overexpression of th e\ntau repeat domain with an FTD-17 mutation (TauRD /Delta1K280)\n(\n252) as well as the proteolytically cleaved tau isoform D421\n(Tau-C3) (260) are degraded by macroautophagy in cell models\nof tauopathy. Interestingly, tau phosphorylated at KXGS motifs\nescapes degradation by the UPS but is eﬃciently degraded\nby macroautophagy (\n252), suggesting the that wild type tau\ncan also be degraded by macroautophagy. As PTMs contribute\nto tau aggregation (see section Eﬀect of PTMs on Tau\nSolubility and Aggregation), they likely regulate tau clearan ce\nvia macroautophagy.\nFailure of tau degradation by the autophagy-lysosomes\npathway has been linked to tauopathies. For example, there\nare several studies suggesting a defect in macroautophagy in\ntauopathy patients (\n261–263). Furthermore, it has been shown\nthat tau in NFTs colocalizes with lysosomes and lysosomal\nmarkers in human AD, CBD, and PSP brains (\n263–267),\nsuggesting that tau is directed toward macroautophagy but\nfails to be degraded. Moreover, evidence from mouse and\nDrosophila models of FTLD-Tau indicates that the microtubule\ndestabilization associated with the abnormal phosphorylatio n\nof tau leads to the disruption of the axonal vesicle transport\nby impairing the dynein-dynactin complex, vesicle traﬃcking ,\nand autophagic ﬂux (\n268, 269). Alterations in CMA may\nFrontiers in Neurology | www.frontiersin.org 12 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\nalso contribute to tauopathies, since it has been described\nthat tau carrying the FTD-related mutation P301L reduces\ntau’s susceptibility for degradation by CMA (\n251). Overall, the\nregulation of the autophagy-lysosomes pathway seems to be\nessential for maintaining tau homeostasis in health and dis ease,\nand PTMs in tau inﬂuence the autophagic degradation of tau in\nmultiple ways.\nEFFECT OF PTMs ON TAU SOLUBILITY\nAND AGGREGATION\nThe degradation pathways discussed above represent a major\ncomponent of the proteostasis network and ensure that, under\nnormal conditions, tau is maintained in an optimally function al\nstate (\n231). However, in tauopathies, there is a breakdown in\ntau homeostasis that in turn leads to aberrant accumulation ,\nmisfolding, and aggregation of tau ( 45, 242, 270). Recent studies\nsuggest that PTMs contribute in sometimes surprising ways to\naltering tau solubility and thereby promoting its aggregati on.\nVarious biophysical techniques have demonstrated that\nunder physiological conditions, tau exists in a “natively\nunfolded” or “intrinsically disordered” state (\n45, 271, 272).\nDespite being intrinsically disordered, tau shows a preferen ce\nfor global interactions between its negatively charged N-\nterminus and positively charged repeat domains, leading\nto an energetically favored “paperclip” like conformation\n(\n273). In contrast to soluble tau, tau aggregates are\ncomposed of β -sheet rich structures known as amyloid\nﬁbrils ( 274–277). Amyloid ﬁbrils are highly heterogeneous\nin nature and are not easily amenable to study via\ntraditional methods used in structural biology. Recent\nbreakthroughs in cryo-electron microscopy (cryo-EM)\ntechnology, however, have made it possible to determine\nhigh resolution three-dimensional structure of tau amyloi d\nﬁbrils (\n278, 279). Determination of the atomic structures\nof tau aggregates may provide a better understanding of\nthe mechanisms underlying their formation, spreading,\nand clearance.\nTo date, cryo-EM has elucidated the structure of tau ﬁlaments\nisolated from brains of patients with several diﬀerent forms\nof tauopathies (\n279–284). According to these studies, each\ntauopathy is associated with a unique tau ﬁlament fold ( 279). The\norigin of such structural speciﬁcity is not yet known, but cou ld\nemanate from PTMs ( 279). For example, tau is phosphorylated at\nS262 in tau ﬁlaments extracted from AD and CBD brains, but\nnot in the ﬁlaments of PiD patients (\n11). Consistent with this\nphospho-modiﬁed residue contributing to aggregate structur e,\nS262 is present in the tau ﬁlament core in PiD but not AD ( 279).\nTherefore, distinctive patterns of post-translational modi ﬁcation\nin diﬀerent tauopathies may underlie not only the structural\nspeciﬁcity of amyloids observed in cryo-EM structures, but c ould\neven contribute to selective vulnerability to these diseas es.\nTo understand the fundamental role of PTMs in tau\naggregation, it is important to account for the inﬂuence of\nPTMs over the charge composition and distribution within a\npolypeptide chain. The net charge on any protein is dependent\non the content of ionizable groups. Net charge is 0 when\nthe pH of the surrounding environment equals that protein’s\nisoelectric point (pI). Similarly, net charge is positive at a pH\nbelow pI, and is negative at pH above its pI. Tau contains\naround 29 percent charged residues, has low hydrophobicity an d\nhas a low net charge of + 2 at physiological pH. While tau is\noverall slightly positively charged, the amino-terminal re sidues\n(including the two N-terminal inserts) are more negatively\ncharged, the microtubule-binding repeat region is predominan tly\npositive, and the distal carboxy-terminal residues are most ly\nneutral (\n285). Such asymmetric distribution of charges has\nbeen proposed to play a crucial role in tau interactions with\nmicrotubules and other binding partners (\n45). It may also explain\nthe inability of tau to undergo aggregation in vitro without\npolyanionic aggregation inducers ( 286–288). The inducers of tau\naggregation are not typically present in neurons but their eﬀec t\nmay be achieved through the masking of charged residues in ta u\nvia PTMs.\nPTMs that make tau more negatively charged are\nphosphorylation, acetylation, and nitration. These PTMs, when\npresent in the microtubule-binding domains, have been proposed\nto initiate tau aggregation by ﬁrst weakening its interacti on with\nnegatively charged microtubules (\n26, 45, 289, 290) The reduced\naﬃnity of tau toward microtubules upon these modiﬁcations\nwould increase the “free” pool of soluble modiﬁed tau molecul es\nthat might have a higher tendency to self-assemble into\naggregates, as has been observed in case of phosphorylated\ntau (\n189, 291). The aggregation might be further promoted by\nelectrostatic interactions between negatively charged, m odiﬁed\ntau and positively charged, unmodiﬁed tau. The eﬀects of\nphosphorylation on tau aggregation, however, seem to be\nsite-dependent. For example, phosphorylation sites close to the\nN-terminus tend to prevent tau aggregation but phosphorylation\nsites in the vicinity of the C-terminus and microtubule-bin ding\nregion seem to accelerate ﬁlament formation in vitro (\n285).\nA similar site-dependence has been observed in tau nitration ,\nwhere depending on the residues that are modiﬁed, nitration\ncan either promote or inhibit tau aggregation (\n230, 289).\nInterestingly, the core of tau ﬁlaments isolated from tauopa thy\npatients contains multiple lysine residues that are susceptibl e to\nacetylation (280, 281, 283). Since the microtubule binding region\nconstitutes a major part of the core of tau ﬁlaments, acetylat ion\nof lysine residues in this region likely plays an important role in\nthe assembly of tau ﬁlaments.\nUnlike phosphorylation, acetylation, and nitration that alter\nthe charge of tau, methylation preserves the positive charge\non lysine residues for a neutral eﬀect on net charge of\nthe protein. The role of methylation in tau aggregation is\ncontroversial and it is unclear whether tau methylation indu ces\ntau aggregation or has a protective role. While some studies h ave\nremarked that methylation at lysine residues facilitates ab normal\nprotein aggregation (\n292, 293), further experimentation using\nrecombinant tau has shown opposite results, demonstrating that\nmethylation reduces the tendency of tau toward aggregation and\npromotes tubulin assembly (\n141). Interestingly, the methylation\nstatus of tau changes from dimethyl- to monomethyl-lysine\nwith aging and disease (\n140). Therefore, it is possible that high\nFrontiers in Neurology | www.frontiersin.org 13 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\nstoichiometry (number of methyl groups/protein molecule) of\nmethylation reduces the propensity of tau toward aggregation in\nvitro and promote tubulin assembly (\n140).\nAnother important modiﬁcation in tau that does not aﬀect\ncharge but can aﬀect tau aggregation is oxidation. The oxidat ion\nat one of the two cysteine residues C-322 (present in R3 repeat)\n(Figure 3) seems to promote tau aggregation into paired helical\nﬁlaments (\n224). However, aggregation is inhibited under reduced\nconditions, upon mutation of cysteine to alanine and upon the\nformation of an intramolecular disulﬁde bond between C-322\nand C-291 (\n224, 294).\nWhile the PTMs described above involve the addition\nof small chemical groups to tau, other PTMs involve the\naddition of large sugar groups (glycosylation and glycation )\nand protein macromolecules (ubiquitination and SUMOylation )\n(Figure 2). These large molecules can have profound steric\neﬀects on the native conformation of tau and therefore can\nstrongly inﬂuence misfolding and aggregation. The mechani sms\nby which glycation and glycosylation regulate tau solubili ty\nand aggregation are poorly understood. Glycation appears to\npromote the polymerization and stabilization of aggregated t au\n(\n295). Additionally, the N-glycosylation of tau is thought to be\nassociated with maintaining the structure of NFTs ( 167). On the\nother hand, O-GlcNAcylation has been proposed to protect tau\nagainst aggregation (\n175). In fact, a study on tau peptides has\nshown that O-GlcNAcylation in proline-rich sequences favor s a\nmore disordered or extended conformation of tau ( 296).\nLike sugars, the eﬀects of ubiquitin and SUMO addition to\ntau on aggregation propensity have not been extensively studi ed.\nHowever, both mono- and polyubiquitination can contribute\nto the formation of insoluble tau inclusions (\n96, 117). In\naddition, a recent cryo-electron microscopy (cryo-EM) and\nmass spectrometry-based study performed on tau ﬁlaments\nisolated from the brains of tauopathy patients, has proposed tha t\nincorporation of ubiquitin into tau ﬁlaments mediates speciﬁ c\ninter-protoﬁlament packing by providing additional contacts\nbetween tau molecules in each protoﬁlament via ubiquitin cha ins\n(\n282). SUMOylation is analogous to ubiquitination and has been\nshown to decrease the solubility of tau ( 128). However, the\nmechanisms by which SUMOylation reduces tau solubility and\nmost likely promotes its aggregation, remain unknown.\nOverall, PTMs on tau critically inﬂuence the assembly of\nnatively unfolded tau into highly ordered β -sheet rich aggregates.\nIt is likely that PTMs drive this process by altering the distin ctive\ncharge distribution on tau. It is worth emphasizing that whil e\nPTMs undoubtedly aﬀect tau solubility and intermolecular\ninteractions, the eﬀect of PTMs on processes such as protein\nlocalization and degradation would also contribute, in a di screte\nand upstream manner, to when, how and why tau aggregation\nevents occur.\nCROSS-TALK AND COMPETITION\nBETWEEN PTMs\nThe PTM code hypothesis proposes that the combination\nof PTMs in proteins generates a dynamic “code” that can\nbe translated into complex biological consequences (\n297).\nThis hypothesis may apply to tau since it undergoes many\nmodiﬁcations, often targeting the same amino acid residue\n(Figure 3). Such heterogeneity and competition between PTMs\nsuggest that tau function and aggregation could be a consequen ce\nof the combination of several PTMs and/or the substitution of\none PTM by another at the same position. In this regard, and\nbased on the evidence described above, it is likely that while s ome\nPTM ensembles are essential for the regulation of tau functi on\nand degradation, others are more deterministic for formati on of\ntau aggregates ( Figure 4).\nOne level at which competing biological outcomes can be\ncoded is via competition of diﬀerent PTMs for the same\namino acid. For example, S and T residues are modiﬁed\nby phosphorylation and O-GlcNAcylation. O-GlcNAcylation\nin some S/T residues protects tau from phosphorylation and\nthus blocks the eﬀects of phosphorylation, which impacts\nmicrotubule-binding aﬃnity and aggregation propensity, on\nthese residues (\n155, 165, 298).\nPerhaps even more interesting are lysine residues, which are\nsusceptible to ﬁve diﬀerent PTMs—acetylation, ubiquitination ,\nmethylation, SUMOylation, and glycation. Each one of these\nmodiﬁcations have potentially diﬀerent consequences for tau\nstructure, function and aggregation. Since ubiquitinatio n occurs\non lysine residues, other lysine-based PTMs may prevent\nubiquitination and therefore impair tau degradation (\n128, 139).\nIn fact, many lysine residues that competent for ubiquitinat ion\nare also targets for other PTMs ( Figure 3). For example, K254\nresidue in tau can undergo ubiquitination and methylation. I n\nﬁbrillar tau, K254 was found to be primarily methylated and\nubiquitinated to a lesser extent, suggesting that methylati on may\nblock UPS-mediated tau degradation and lead to an increase in\ntau levels (\n89). Like methylation, acetylation could potentially\nprevent lysine ubiquitination, resulting in the insuﬃcient\nturnover endogenous tau (\n72). The veritable log jam of PTMs\nthat can be found on lysine residues marks this amino acid as\na particularly interesting and likely important site at which c ells\norchestrate the biological outcomes they wish to achieve wit h tau\nand other proteins.\nIn addition to competition, crosstalk between PTMs can also\nbe achieved through cooperativity. Some studies suggest tha t\ncertain PTMs make tau more amenable to other modiﬁcations.\nIn vitro tau SUMOylation seemingly enhances phosphorylation\nat residues such as T231 and S262 (\n128). Other studies have\nshown that tau methylation at K267 may result in subsequent\nand possibly abnormal phosphorylation of tau at S262 (\n89).\nIt has also been proposed that N-glycosylation precedes\ntau phosphorylation (\n299). In each of these cases, though,\na reasonable alternative interpretation is that SUMOylation ,\nmethylation, or N-glycosylation may impair tau clearance,\nenhancing the half-life of tau in the cytosol, and thus, provid ing\nmore opportunities for phosphorylation.\nOn the other hand, phosphorylation can also aﬀect the\npropensity of tau for other PTMs. For example, in speciﬁc\nexperimental conditions the in vitro phosphorylation\nof tau in the microtubule binding domain activates tau\nautoacetyltransferase activity and therefore promote its\nFrontiers in Neurology | www.frontiersin.org 14 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\nFIGURE 4 | Post-translational modiﬁcations on tau impact tau function , degradation, and aggregation. PTMs can both promote and in hibit tau function, clearance,\nand aggregation. A non-exhaustive list of examples are illu strated here. In many cases, it is likely that cross-talk and c ompetition between PTMs results in the speciﬁc\nand dynamic regulation of tau.\nacetylation ( 76). Furthermore, a protective role of the\nswitch between tau phosphorylation and acetylation has\nbeen described. The acetylation of tau at KXGS motifs\ninhibits phosphorylation and thus prevents the detachment\nof tau from microtubules and its aggregation (\n34, 247).\nAdditionally, the phosphorylation of tau at S422 seems to\nprecede and block the cleavage of tau at D421 by caspase-3 (\n300),\nsuggesting that phosphorylation at S422 could be a protective\nmechanism for the inhibition of the caspase-mediated cleava ge\nof tau.\nTaken together, the current literature suggests that cross talk,\ncombinations, and competition between PTMs play a\ncritical role in tau function, degradation, and aggregatio n.\nAn old truism states that “We are the company we keep.”\nIf so, then future studies dedicated to documenting and\ndecoding ensembles of tau PTMs will rise in importance\nin regards to understanding and developing interventions\nfor tauopathies.\nAPPROACHES AND LIMITATIONS\nThe complete understanding of the role of PTMs in tau\nfunction and dysfunction is obstructed by several limitati ons\nin the methodology and models used. Historically, PTMs were\nidentiﬁed using immunochemistry-based approaches. Using th is\nmethod, several phosphorylation sites were identiﬁed and thu s,\na large number of anti-phospho tau antibodies are available\n(\n301). While immunochemistry methods are routinely used and\nare highly eﬀective for the characterization tauopathies, th ey do\nnot provide a comprehensive and quantitative description of\nPTMs, nor do they distinguish between single molecules with\nmany PTMs vs. many molecules with single PTMs (\n302). Some\nof these problems can be solved by the use of quantitative\nmass spectrometry (MS) and nuclear magnetic resonance (NMR)\nspectroscopy, which provide a more detailed description of\nPTMs and allow the simultaneous analyses of a variety of\nPTMs (\n89, 110, 303–308). However, most of these methods are\nbiased toward the peptides of highest intensity, and prevent th e\naccurate determination of site-speciﬁc stoichiometry, ass ociated\nsite-speciﬁc dynamics and identiﬁcation of labile PTMs like\nprotonation (\n302). The high percentage of PTM sites in tau adds\nto the complexity, making it incredibly challenging to design and\ncarry out such studies. To overcome some of these challenges ,\nanalytical methods including one known as FLEXITau (Full-\nLength Expressed stable Isotope-labeled tau) have been recen tly\ndeveloped (\n309). This method allows for unbiased analyses of\ntau PTMs in a more quantitative manner. In this regard, a study\nusing FLEXITau has reported 95 PTMs on tau isolated from\npostmortem human tissue from AD and has demonstrated that\nthese modiﬁcations occur in an ordered manner and lead to tau\naggregation (\n310).\nThe choice of models to use for studying PTMs also inﬂuences\nthe understanding of the eﬀect of PTMs in tau biology. The vast\nmajority of PTMs have been identiﬁed in vitro, using biochemical\nassays where puriﬁed tau protein was incubated with speciﬁc\nenzymes (\n71) or using tau/enzymes overexpression systems in\ncell models ( 128). Some PTMs have also been conﬁrmed or\nidentiﬁed in vivo using tauopathy mouse models. However, most\nof these models are based on the expression of mutant forms\nhuman tau, and whether those ﬁndings and insights into PTMs\nextends to wild-type tau and sporadic tauopathies remains to be\nseen (\n79).\nFrontiers in Neurology | www.frontiersin.org 15 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\nTau PTMs have also been studied in post-mortem human\nbrains using immunochemistry techniques and cryo-EM ( 282).\nIt is important to keep in consideration that some PTMs can\nbe lost or degraded during the process of brain extraction,\nﬁxation, storage, and analysis. Therefore, it is possible tha t in\nstudies performed on human brain extracts, some tau PTMs may\nnot be identiﬁed because of the caveats associated with brai n\npreparation processes (\n37).\nThe cross-talk between PTMs is very important for the\nregulation of function, structure, and degradation of the pr oteins.\nMany studies on tau PTMs have focused only on one type of\nmodiﬁcation. Extrapolation of results obtained from single P TM\nstudies lack context in regard to cross-talk and competition .\nAs a result, a major caveat of many studies is the inability to\ndiﬀerentiate between causes, consequences and bystander eﬀe cts\nof these PTMs. The understanding of and solution to these\nlimitations may enable the discovery of a “PTM code” in tau th at\nwill help to deﬁne sensitive biomarkers and lead to insights into\ndisease pathobiology. In addition, unravelling the speciﬁc e ﬀects\nof PTMs in tau biology will pave the road toward new therapeutic\napproaches for tau-related neurodegenerative diseases.\nCONCLUDING REMARKS\nPTMs are essential to the normal function of tau and therefore\nalterations in the pattern of PTMs has the potential to lead\nto tau dysfunction, accumulation, and abnormal aggregatio n.\nPTMs exert their function either through altering protein\nelectrostatics or conferring steric alterations. Among al l tau\nPTMs, phosphorylation has been studied most extensively and\nhistorically, was thought to hold primacy in regulating tau\nfunction and pathogenesis of tauopathies. However, increasi ng\nevidence suggests that many other PTMs contribute to dynamic\nregulation of tau. Cross-talk and competition between PTMs, in\nparticular at lysine residues, introduce an intriguing new l ayer of\ncomplexity to orchestration of tau function and dysfunction. At\nthe same time, combinatorial ensembles of PTMs may emerge as\na means by which cells achieve diﬀerential biological outcom es\ninvolving tau. As a robust and fast-moving area of investiga tion,\ntau post-translational modiﬁcation will likely impact the bas ic,\npre-clinical, and clinical-translational aspects of tau biolog y in\ninteresting ways for years to come.\nAUTHOR CONTRIBUTIONS\nCA and SA performed the literature review. CA, SA, and AK\nwrote the manuscript. All authors agreed to the ﬁnal version o f\nthe manuscript.\nFUNDING\nTau consortium, P30 P0531421, R01 NS095257, R01 AG059052,\nChan Zuckerberg Initiative grant.\nACKNOWLEDGMENTS\nWe gratefully acknowledge Jacqueline Jia for artistic\ncontributions to ﬁgure preparation. We thank Dr. Alma\nBurlingame and Dr. William Seeley for critical review of\nthe manuscript.\nREFERENCES\n1. Walsh CT. Posttranslational Modiﬁcation of Proteins: Expanding Nat ure’s\nInventory - Christopher Walsh - Google Libros . Greenwood Village, CO:\nRoberts and Company, Publishers (2006) Available online at: https:/ /\nbooks.google.com/books?hl=es&lr=&id=JGBfQXIzdwgC&oi=fnd&pg=\nPP21&ots=v8ZAw__wOI&sig=owJxdEEdGvj8IHuiAf6pMUkowWM#v=\nonepage&q&f=false (accessed August 14, 2020).\n2. Smith LM, Kelleher NL. Proteoform: a single term describing protein\ncomplexity. Nat Methods. (2013) 10:186–7. doi: 10.1038/nmeth.2369\n3. Darling AL, Uversky VN. Intrinsic disorder and posttranslationa l\nmodiﬁcations: the darker side of the biological dark matter. Front Genet.\n(2018) 9:158. doi: 10.3389/fgene.2018.00158\n4. Barber KW, Rinehart J. The ABCs of PTMs. Nat Chem Biol. (2018) 14:188–\n92. doi: 10.1038/nchembio.2572\n5. Ravid T, Hochstrasser M. Diversity of degradation signals in t he\nubiquitin-proteasome system. Nat Rev Mol Cell Biol. (2008) 9:679–\n89. doi: 10.1038/nrm2468\n6. Uversky VN. Natively unfolded proteins: a point where biology wai ts for\nphysics. Protein Sci. (2002) 11:739–56. doi: 10.1110/ps.4210102\n7. Uversky VN. Intrinsically disordered proteins and their (disorde red)\nproteomes in neurodegenerative disorders. Front Aging Neurosci. (2015)\n7:18. doi: 10.3389/fnagi.2015.00018\n8. Dyson HJ. Expanding the proteome: disordered and\nalternatively folded proteins. Q Rev Biophys. (2011) 44:467–\n518. doi: 10.1017/S0033583511000060\n9. Jeganathan S, Von Bergen M, Mandelkow EM, Mandelkow E. The na tively\nunfolded character of tau and its aggregation to Alzheimer-like pai red helical\nﬁlaments. Biochemistry. (2008) 47:10526–39. doi: 10.1021/bi800783d\n10. Buee L, Bussiere T, Buee-Scherrer V , Delacourte A, Hof PR. Tau prot ein\nisoforms, phosphorylation and role in neurodegenerative disorders. Brain\nRes Brain Res Rev. (2000) 33:95–130. doi: 10.1016/S0165-0173(00)00019-9\n11. Goedert M, Eisenberg DS, Crowther RA. Propagation of tau\naggregates and neurodegeneration. Annu Rev Neurosci. (2017)\n40:189–210. doi: 10.1186/s13041-017-0298-7\n12. Dixit R, Ross JL, Goldman YE, Holzbaur ELF. Diﬀerential regulati on\nof dynein and kinesin motor proteins by tau. Science. (2008) 319:1086–\n9. doi: 10.1126/science.1152993\n13. Zuo YC, Li HL, Xiong NX, Shen JY, Huang YZ, Fu P , et al. Overexpressio n of\nTau rescues nogo-66-induced neurite outgrowth inhibition in vitro. Neurosci\nBull. (2016) 32:577–84. doi: 10.1007/s12264-016-0068-z\n14. Merino-Serrais P , Benavides-Piccione R, Blazquez-Llorca L, Kastanauskaite\nA, Rá A, Avila JS, et al. The inﬂuence of phospho-tau on dendritic spi nes\nof cortical pyramidal neurons in patients with Alzheimer’s disease. Brain.\n(2013) 136:1913–28. doi: 10.1093/brain/awt088\n15. Brandt R, Léger J, Lee G. Interaction of tau with the neural plas ma membrane\nmediated by tau’s amino-terminal projection domain. J Cell Biol. (1995)\n131:1327–40. doi: 10.1083/jcb.131.5.1327\n16. Farah CA, Perreault S, Liazoghli D, Desjardins M, Anton A, Lauzo n\nM, et al. Tau interacts with golgi membranes and mediates their\nassociation with microtubules. Cell Motil Cytoskeleton. (2006) 63:710–\n24. doi: 10.1002/cm.20157\n17. Meier S, Bell M, Lyons DN, Ingram A, Chen J, Gensel JC, et al. Id entiﬁcation\nof novel tau interactions with endoplasmic reticulum proteins in Alzh eimer’s\ndisease brain. J Alzheimer’s Dis.(2015) 48:687–702. doi: 10.3233/JAD-150298\n18. Noble W, Hanger DP , Miller CCJ, Lovestone S. The importance of\ntau phosphorylation for neurodegenerative diseases. Front Neurol. (2013)\n4:83. doi: 10.3389/fneur.2013.00083\nFrontiers in Neurology | www.frontiersin.org 16 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\n19. Kampers T, Friedhoﬀ P , Biernat J, Mandelkow EM, Mandelkow E.\nRNA stimulates aggregation of microtubule-associated protein tau i nto\nAlzheimer-like paired helical ﬁlaments. FEBS Lett. (1996) 399:344–\n9. doi: 10.1016/S0014-5793(96)01386-5\n20. Krylova SM, Musheev M, Nutiu R, Li Y, Lee G, Krylov SN. Tau protein\nbinds single-stranded DNA sequence speciﬁcally - the proof obtaine d\nin vitro with non-equilibrium capillary electrophoresis of equilibrium\nmixtures. FEBS Lett. (2005) 579:1371–5. doi: 10.1016/j.febslet.2005.\n01.032\n21. Sultan A, Nesslany F, Violet M, Bégard S, Loyens A, Talahari S, et al.\nNuclear tau, a key player in neuronal DNA protection. J Biol Chem. (2011)\n286:4566–75. doi: 10.1074/jbc.M110.199976\n22. Arendt T, Stieler JT, Holzer M. Tau and tauopathies. Brain Res Bull. (2016)\n126:238–92. doi: 10.1016/j.brainresbull.2016.08.018\n23. Park S, Lee JH, Jeon JH, Lee MJ. Degradation or aggregation: the\nramiﬁcations of post-translational modiﬁcations on tau. BMB Rep. (2018)\n51:265–23. doi: 10.5483/BMBRep.2018.51.6.077\n24. Haj-Yahya M, Lashuel HA. Protein semisynthesis provides acc ess to Tau\ndisease-associated post-translational modiﬁcations (PTMs) a nd paves the\nway to deciphering the tau PTM code in health and diseased states . J Am\nChem Soc. (2018) 140:6611–21. doi: 10.1021/jacs.8b02668\n25. Hanger DP , Anderton BH, Noble W. Tau phosphorylation: the therapeu tic\nchallenge for neurodegenerative disease. Trends Mol Med. (2009) 15:112–\n9. doi: 10.1016/j.molmed.2009.01.003\n26. Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP , Trojanowski JQ , et al.\nThe acetylation of tau inhibits its function and promotes patholog ical tau\naggregation. Nat Commun. (2011) 2:252. doi: 10.1038/ncomms1255\n27. Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VMY, et al.\nAcetylated tau, a novel pathological signature in Alzheimer’s dis ease and\nother tauopathies. Brain. (2012) 135:807–18. doi: 10.1093/brain/aws013\n28. Guillozet-Bongaarts AL, Glajch KE, Libson EG, Cahill ME, Bigi o E, Berry\nRW, et al. Phosphorylation and cleavage of tau in non-AD tauopathie s. Acta\nNeuropathol. (2007) 113:513–20. doi: 10.1007/s00401-007-0209-6\n29. Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, Horowitz PM,\nFu Y, Wang T, et al. Tau truncation during neuroﬁbrillary tangle\nevolution in Alzheimer’s disease. Neurobiol Aging. (2005) 26:1015–\n22. doi: 10.1016/j.neurobiolaging.2004.09.019\n30. Sacco F, Perfetto L, Castagnoli L, Cesareni G. The human phosph atase\ninteractome: an intricate family portrait. FEBS Lett. (2012) 586:2732–\n9. doi: 10.1016/j.febslet.2012.05.008\n31. Humphrey SJ, James DE, Mann M. Protein phosphorylation: a major switc h\nmechanism for metabolic regulation. Trends Endocrinol Metab. (2015)\n26:676–87. doi: 10.1016/j.tem.2015.09.013\n32. Hunter T. Protein kinases and phosphatases: the yin and\nyang of protein phosphorylation and signaling. Cell. (1995)\n80:225–36. doi: 10.1016/0092-8674(95)90405-0\n33. Ardito F, Giuliani M, Perrone D, Troiano G, Muzio LL. The crucial role of\nprotein phosphorylation in cell signalingand its use as targeted the rapy. Int J\nMol Med. (2017) 40:271–80. doi: 10.3892/ijmm.2017.3036\n34. Reynolds CH, Betts JC, Blackstock WP , Nebreda AR, Anderton\nBH. Phosphorylation sites on tau identiﬁed by nanoelectrospray\nmass spectrometry: diﬀerences in vitro between the mitogen-\nactivated protein kinases ERK2, c-Jun N-terminal kinase and\nP38, and glycogen synthase kinase- 3 β . J Neurochem. (2000)\n74:1587–95. doi: 10.1046/j.1471-4159.2000.0741587.x\n35. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Yoshi da H,\nTitani K, et al. Proline-directed and non-proline-directed phosphoryla tion\nof PHF-tau. J Biol Chem. (1995) 270:823–9. doi: 10.1074/jbc.270.2.823\n36. Cook C, Stankowski JN, Carlomagno Y, Stetler C, Petrucelli L. Ace tylation:\na new key to unlock tau’s role in neurodegeneration . Alzheimer’s Res Ther.\n(2014). 6:29. doi: 10.1186/alzrt259\n37. Matsuo ES, Shin RW, Billingsley ML, van deVoorde A,\nO’Connor M, Trojanowski JQ, et al. Biopsy-derived adult human\nbrain tau is phosphorylated at many of the same sites as\nAlzheimer’s disease paired helical ﬁlament tau. Neuron. (1994)\n13:989–1002. doi: 10.1016/0896-6273(94)90264-X\n38. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, et al.\nCurrent advances on diﬀerent kinases involved in tau phosphorylatio n, and\nimplications in Alzheimers disease and tauopathies. Curr Alzheimer Res.\n(2005) 2:3–18. doi: 10.2174/1567205052772713\n39. Ji C, Tang M, Zeidler C, Höhfeld J, Johnson GVW. BAG3\nand SYNPO (synaptopodin) facilitate phospho-MAPT/Tau\ndegradation via autophagy in neuronal processes. Autophagy. (2019)\n15:1199–213. doi: 10.1080/15548627.2019.1580096\n40. Derkinderen P , Scales TME, Hanger DP , Leung KY, Byers HL, Ward M A, et\nal. Tyrosine 394 is phosphorylated in Alzheimer’s paired helical ﬁlament t au\nand in fetal tau with c-Abl as the candidate tyrosine kinase. J Neurosci. (2005)\n25:6584–93. doi: 10.1523/JNEUROSCI.1487-05.2005\n41. Vega IE, Cui L, Propst JA, Hutton ML, Lee G, Yen SH. Increase in ta u\ntyrosine phosphorylation correlates with the formation of tau aggregat es.\nMol Brain Res. (2005) 138:135–44. doi: 10.1016/j.molbrainres.2005.04.015\n42. Gong C -X, Singh TJ, Grundke-Iqbal I, Iqbal K. Phosphoprotein ph osphatase\nactivities in Alzheimer disease brain. J Neurochem. (1993) 61:921–\n7. doi: 10.1111/j.1471-4159.1993.tb03603.x\n43. Braithwaite SP , Stock JB, Lombroso PJ, Nairn AC. Protein\nphosphatases and Alzheimer’s disease. Prog Mol Biol Transl Sci .\n106:343–79. doi: 10.1016/B978-0-12-396456-4.00012-2\n44. Wadhwa P , Jain P , Jadhav HR. Glycogen synthase kinase 3\n(GSK3): its role and inhibitors. Curr Top Med Chem. (2020)\n20:1522–34. doi: 10.2174/1568026620666200516153136\n45. Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein\nin neuroﬁbrillary degeneration. Cold Spring Harb Perspect Biol. (2012)\n4:ea006247. doi: 10.1101/cshperspect.a006247\n46. Yu Y, Run X, Liang Z, Li Y, Liu F, Liu Y, et al. Developmental regulat ion of\ntau phosphorylation, tau kinases, and tau phosphatases. J Neurochem. (2009)\n108:1480–94. doi: 10.1111/j.1471-4159.2009.05882.x\n47. Biernat J, Mandelkow E-M. The development of cell processes induc ed by tau\nprotein requires phosphorylation of serine 262 and 356 in the repeat domai n\nand is inhibited by phosphorylation in the proline-rich domains. Mol Biol\nCell. (1999) 10:727–40. doi: 10.1091/mbc.10.3.727\n48. Drewes G, Trinczek B, Illenberger S, Biernat J, Schmitt-Ulms G,\nMeyer HE, et al. Microtubule-associated protein/microtubule aﬃnity -\nregulating kinase (p110(mark)). a novel protein kinase that regulate s tau-\nmicrotubule interactions and dynamic instability by phosphorylation at\nthe Alzheimer- speciﬁc site serine 262. J Biol Chem. (1995) 270:7679–\n88. doi: 10.1074/jbc.270.13.7679\n49. Biernat J, Gustke N, Drewes G, Mandelkow E, Mandelkow E.\nPhosphorylation of Ser262 strongly reduces binding of tau to microtub ules:\ndistinction between PHF-like immunoreactivity and microtubule bin ding.\nNeuron. (1993) 11:153–63. doi: 10.1016/0896-6273(93)90279-Z\n50. Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci.\n(2016) 17:5–21. doi: 10.1038/nrn.2015.1\n51. Mandel JE, Banker GA. Microtubule-associated proteins, phos phorylation\ngradients, and the establishment of neuronal polarity. Perspect Dev\nNeurobiol. (1996) 4:125–35.\n52. Mandell JW, Banker GA. A spatial gradient of tau protein\nphosphorylation in nascent axons. J Neurosci. (1996) 16:5727–\n40. doi: 10.1523/JNEUROSCI.16-18-05727.1996\n53. Biernat J, Wu YZ, Timm T, Zheng-Fischhöfer Q, Mandelkow E, Me ijer\nL, et al. Protein kinase MARK/PAR-1 is required for neurite outgrow th\nand establishment of neuronal polarity. Mol Biol Cell. (2002) 13:4013–\n28. doi: 10.1091/mbc.02-03-0046\n54. Li C, Götz J. Somatodendritic accumulation of tau in Alzheimer’ s disease\nis promoted by Fyn-mediated local protein translation. EMBO J. (2017)\n36:3120–38. doi: 10.15252/embj.201797724\n55. Ittner LM, Ke YD, Götz J. Phosphorylated tau interacts with c- Jun N-\nterminal kinase-interacting protein 1 (JIP1) in Alzheimer disease . J Biol\nChem. (2009) 284:20909–16. doi: 10.1074/jbc.M109.014472\n56. Lu PJ, Wulf G, Zhou XZ, Davies P , Lu KP. The prolyl isomerase Pin1 res tores\nthe function of Alzheimer-associated phosphorylated tau protein. Nature.\n(1999) 399:784–8. doi: 10.1038/21650\n57. Cho JH, Johnson GVW. Glycogen synthase kinase 3 β phosphorylates tau at\nboth primed and unprimed sites: diﬀerential impact on microtubule bindin g.\nJ Biol Chem. (2003) 278:187–93. doi: 10.1074/jbc.M206236200\n58. Cho JH, Johnson GVW. Primed phosphorylation of tau at Thr231 by\nglycogen synthase kinase 3 β (GSK3β ) plays a critical role in regulating tau’s\nFrontiers in Neurology | www.frontiersin.org 17 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\nability to bind and stabilize microtubules. J Neurochem. (2004) 88:349–\n58. doi: 10.1111/j.1471-4159.2004.02155.x\n59. Dawson HN, Ferreira A, Ghoshal N, Eyster MV , Binder LI, Vitek M P.\nInhibition of neuronal maturation in primary hippocampal neurons from\nτ deﬁcient mice. J Cell Sci. (2001) 114:1179–87.\n60. Spittaels K, van Den Haute C, van Dorpe J, Geerts H, Mercken M,\nBruynseels K, et al. Glycogen synthase kinase-3 β phosphorylates protein\ntau and rescues the axonopathy in the central nervous system of\nhuman four-repeat tau transgenic mice. J Biol Chem. (2000) 275:41340–\n9. doi: 10.1074/jbc.M006219200\n61. Tatebayashi Y, Haque N, Tung YC, Iqbal K, Grundke-Iqbal I. Role of\ntau phosphorylation by glycogen synthase kinase-3 β in the regulation of\norganelle transport. J Cell Sci. (2004) 117:1653–63. doi: 10.1242/jcs.01018\n62. Jaworski T, Kügler S, van Leuven F. Modeling of tau-mediated synaptic and\nneuronal degeneration in Alzheimer’s disease. Int J Alzheimer’s Dis. (2010)\n2010:573138. doi: 10.4061/2010/573138\n63. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK,\net al. Tau mislocalization to dendritic spines mediates synaptic\ndysfunction independently of neurodegeneration. Neuron. (2010)\n68:1067–81. doi: 10.1016/j.neuron.2010.11.030\n64. Thies E, Mandelkow EM. Missorting of tau in neurons causes de generation\nof synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci.\n(2007) 27:2896–907. doi: 10.1523/JNEUROSCI.4674-06.2007\n65. Hasegawa M, Jakes R, Crowther RA, Lee VMY, Ihara Y, Goedert M.\nCharacterization of mAb AP422, a novel phosphorylation-dependent\nmonoclonal antibody against tau protein. FEBS Lett. (1996) 384:25–\n30. doi: 10.1016/0014-5793(96)00271-2\n66. Haase C, Stieler JT, Arendt T, Holzer M. Pseudophosphorylation of tau\nprotein alters its ability for self-aggregation. J Neurochem. (2004) 88:1509–\n20. doi: 10.1046/j.1471-4159.2003.02287.x\n67. Drazic A, Myklebust LM, Ree R, Arnesen T. The world of protein\nacetylation. Biochim Biophys Acta - Proteins Proteomics. (2016) 1864:1372–\n401. doi: 10.1016/j.bbapap.2016.06.007\n68. Ali I, Conrad RJ, Verdin E, Ott M. Lysine acetylation goes globa l: from\nepigenetics to metabolism and therapeutics. Chem Rev. (2018) 118:1216–\n52. doi: 10.1021/acs.chemrev.7b00181\n69. Strahl BD, Allis CD. The language of covalent histone modiﬁcati ons. Nature.\n(2000) 403:41–5. doi: 10.1038/47412\n70. Narita T, Weinert BT, Choudhary C. Functions and mechanisms of\nnon-histone protein acetylation. Nat Rev Mol Cell Biol. (2019) 20:156–\n74. doi: 10.1038/s41580-018-0081-3\n71. Kamah A, Huvent I, Cantrelle FX, Qi H, Lippens G, Landrieu I, et al. Nucle ar\nmagnetic resonance analysis of the acetylation pattern of the neuro nal tau\nprotein. Biochemistry. (2014) 53:3020–32. doi: 10.1021/bi500006v\n72. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V , Seeley WW, e t\nal. Acetylation of tau inhibits its degradation and contributes to tauopathy.\nNeuron. (2010) 67:953–66. doi: 10.1016/j.neuron.2010.08.044\n73. Ding H, Dolan PJ, Johnson GVW. Histone deacetylase 6 interacts with\nthe microtubule-associated protein tau. J Neurochem. (2008) 106:2119–\n30. doi: 10.1111/j.1471-4159.2008.05564.x\n74. Min SW, Sohn PD, Li Y, Devidze N, Johnson JR, Krogan\nNJ, et al. SIRT1 deacetylates tau and reduces pathogenic tau\nspread in a mouse model of tauopathy. J Neurosci. (2018)\n38:3680–8. doi: 10.1523/JNEUROSCI.2369-17.2018\n75. Carlomagno Y, Chung D eun C, Yue M, Castanedes-Casey M, Madde n\nBJ, Dunmore J, et al. An acetylation–phosphorylation switch that regu lates\ntau aggregation propensity and function. J Biol Chem. (2017) 292:15277–\n86. doi: 10.1074/jbc.M117.794602\n76. Cohen TJ, Friedmann D, Hwang AW, Marmorstein R, Lee VMY. The\nmicrotubule-associated tau protein has intrinsic acetyltransferas e activity.\nNat Struct Mol Biol. (2013) 20:756–62. doi: 10.1038/nsmb.2555\n77. Paik WK, Pearson D, Lee HW, Kim S. Nonenzymatic acetylation o f histones\nwith acetyl-CoA. BBA Sect Nucleic Acids Protein Synth. (1970) 213:513–\n22. doi: 10.1016/0005-2787(70)90058-4\n78. Morris M, Knudsen GM, Maeda S, Trinidad JC, Ioanoviciu A, Burli ngame\nAL, et al. Tau post-translational modiﬁcations in wild-type and huma n\namyloid precursor protein transgenic mice. Nat Neurosci. (2015) 18:1183–\n9. doi: 10.1038/nn.4067\n79. Min SW, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, et al.\nCritical role of acetylation in tau-mediated neurodegeneration an d\ncognitive deﬁcits. Nat Med. (2015) 21:1154–62. doi: 10.1038/nm.\n3951\n80. Chen X, Li Y, Wang C, Tang Y, Mok SA, Tsai RM, et al. Promoting\ntau secretion and propagation by hyperactive p300/CBP via\nautophagy-lysosomal pathway in tauopathy. Mol Neurodegener. (2020)\n15:2. doi: 10.1186/s13024-019-0354-0\n81. Schueller E, Paiva I, Blanc F, Wang XL, Cassel JC, Boutillier AL, et al.\nDysregulation of histone acetylation pathways in hippocampus and fro ntal\ncortex of Alzheimer’s disease patients. Eur Neuropsychopharmacol. (2020)\n33:101–16. doi: 10.1016/j.euroneuro.2020.01.015\n82. Chatterjee S, Cassel R, Schneider-Anthony A, Merienne K, Cosquer B,\nTzeplaeﬀ L, et al. Reinstating plasticity and memory in a tauopathy\nmouse model with an acetyltransferase activator. EMBO Mol Med. (2018)\n10:e8587. doi: 10.15252/emmm.201708587\n83. Julien C, Tremblay C, Émond V , Lebbadi M, Salem N, Bennett\nDA, Calon F. Sirtuin 1 reduction parallels the accumulation\nof tau in alzheimer disease. J Neuropathol Exp Neurol. (2009)\n68:48–58. doi: 10.1097/NEN.0b013e3181922348\n84. Rizzi L, Roriz-Cruz M. Sirtuin 1 and Alzheimer’s disease: an up- to-\ndate review. Neuropeptides. (2018) 71:54–60. doi: 10.1016/j.npep.2018.\n07.001\n85. Luo Y, Ma B, Nussinov R, Wei G. Structural insight into tau prot ein’s paradox\nof intrinsically disordered behavior, self-acetylation activity , and aggregation.\nJ Phys Chem Lett. (2014) 5:3026–31. doi: 10.1021/jz501457f\n86. Irwin DJ, Cohen TJ, Grossman M, Arnold SE, McCarty-Wood\nE, van Deerlin VM, et al. Acetylated tau neuropathology\nin sporadic and hereditary tauopathies. Am J Pathol. (2013)\n183:344–351. doi: 10.1016/j.ajpath.2013.04.025\n87. Grinberg LT, Wang X, Wang C, Sohn PD, Theoﬁlas P ,\nSidhu M, et al. Argyrophilic grain disease diﬀers from other\ntauopathies by lacking tau acetylation. Acta Neuropathol. (2013)\n125:581–93. doi: 10.1007/s00401-013-1080-2\n88. Yang XJ, Seto E. Lysine acetylation: codiﬁed crosstalk with\nother posttranslational modiﬁcations. Mol Cell. (2008) 31:449–\n61. doi: 10.1016/j.molcel.2008.07.002\n89. Thomas SN, Funk KE, Wan Y, Liao Z, Davies P , Kuret J, et al. Dual\nmodiﬁcation of Alzheimer’s disease PHF-tau protein by lysine methyla tion\nand ubiquitylation: a mass spectrometry approach. Acta Neuropathol. (2012)\n123:105–17. doi: 10.1007/s00401-011-0893-0\n90. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. (1998)\n67:425–79. doi: 10.1146/annurev.biochem.67.1.425\n91. Behrends C, Harper JW. Constructing and decoding\nunconventional ubiquitin chains. Nat Struct Mol Biol. (2011)\n18:520–8. doi: 10.1038/nsmb.2066\n92. Cappadocia L, Lima CD. Ubiquitin-like protein conjugation:\nstructures, chemistry, and mechanism. Chem Rev. (2018)\n118:889–918. doi: 10.1021/acs.chemrev.6b00737\n93. Ikeda F, Dikic I. Atypical ubiquitin chains: new molecular si gnals. “Protein\nmodiﬁcations: beyond the usual suspects” Review series. EMBO Rep. (2008)\n9:536–42. doi: 10.1038/embor.2008.93\n94. Nathan JA, Tae Kim H, Ting L, Gygi SP , Goldberg AL. Why do cellula r\nproteins linked to K63-polyubiquitin chains not associate with pro teasomes?\nEMBO J. (2013) 32:552–65. doi: 10.1038/emboj.2012.354\n95. Mukhopadhyay D, Riezman H. Proteasome-independent functions\nof ubiquitin in endocytosis and signaling. Science. (2007)\n315:201–5. doi: 10.1126/science.1127085\n96. Tan JMM, Wong ESP , Kirkpatrick DS, Pletnikova O, Ko HS, Tay S-P , et\nal. Lysine 63-linked ubiquitination promotes the formation and aut ophagic\nclearance of protein inclusions associated with neurodegenerativ e diseases.\nHum Mol Genet. (2008) 17:431–9. doi: 10.1093/hmg/ddm320\n97. Munari F, Barracchia CG, Parolini F, Tira R, Bubacco L, Assfalg M, et\nal. Semisynthetic modiﬁcation of tau protein with di-ubiquitin c hains for\naggregation studies. Int J Mol Sci. (2020) 21:4400. doi: 10.3390/ijms21124400\n98. Harris LD, Jasem S, Licchesi JDF. The ubiquitin system in\nAlzheimer’s disease. Adv Exp Med Biol. (2020) 1233:195–\n221. doi: 10.1007/978-3-030-38266-7_8\nFrontiers in Neurology | www.frontiersin.org 18 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\n99. Zheng N, Shabek N. Ubiquitin ligases: structure, function,\nand regulation. Annu Rev Biochem. (2017) 86:129–\n57. doi: 10.1146/annurev-biochem-060815-014922\n100. Babu JR, Geetha T, Wooten MW. Sequestosome 1/p62 shuttles\npolyubiquitinated tau for proteasomal degradation. J Neurochem. (2005)\n94:192–203. doi: 10.1111/j.1471-4159.2005.03181.x\n101. Flach K, Ramminger E, Hilbrich I, Arsalan-Werner A, Albrecht F,\nHerrmann L, et al. Axotrophin/MARCH7 acts as an E3 ubiquitin\nligase and ubiquitinates tau protein in vitro impairing microtubule\nbinding. Biochim Biophys Acta - Mol Basis Dis. (2014) 1842:1527–\n38. doi: 10.1016/j.bbadis.2014.05.029\n102. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, e t al. CHIP\nand Hsp70 regulate tau ubiquitination, degradation and aggregat ion. Hum\nMol Genet. (2004) 13:703–14. doi: 10.1093/hmg/ddh083\n103. Shimura H, Schwartz D, Gygi SP , Kosik KS. CHIP-Hsc70 complex\nubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem.\n(2004) 279:4869–76. doi: 10.1074/jbc.M305838200\n104. Zhang YJ, Xu YF, Liu XH, Li D, Yin J, Liu YH, et al. Carboxyl terminu s\nof heat-shock cognate 70-interacting protein degrades tau regard less its\nphosphorylation status without aﬀecting the spatial memory of the rat s. J\nNeural Transm. (2008) 115:483–91. doi: 10.1007/s00702-007-0857-7\n105. Moscat J, Diaz-Meco MT, Wooten MW. Signal integration an d\ndiversiﬁcation through the p62 scaﬀold protein. Trends Biochem Sci.\n(2007) 32:95–100. doi: 10.1016/j.tibs.2006.12.002\n106. Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wo oten\nMW. Sequestosome 1/p62 is a polyubiquitin chain binding protein in volved\nin ubiquitin proteasome degradation. Mol Cell Biol. (2004) 24:8055–\n68. doi: 10.1128/MCB.24.18.8055-8068.2004\n107. Seibenhener ML, Geetha T, Wooten MW. Sequestosome 1/p62 - more than\njust a scaﬀold. FEBS Lett. (2007) 581:175–9. doi: 10.1016/j.febslet.2006.12.027\n108. Wang P , Joberty G, Buist A, Vanoosthuyse A, Stancu IC, Vas concelos\nB, et al. Tau interactome mapping based identiﬁcation of Otub1\nas tau deubiquitinase involved in accumulation of pathological\ntau forms in vitro and in vivo . Acta Neuropathol. (2017)\n133:731–49. doi: 10.1007/s00401-016-1663-9\n109. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M,\nTitani K, Ihara Y. Ubiquitin is conjugated with amino-terminally\nprocessed tau in paired helical ﬁlaments. Neuron. (1993)\n10:1151–60. doi: 10.1016/0896-6273(93)90063-W\n110. Cripps D, Thomas SN, Jeng Y, Yang F, Davies P , Yang AJ. Alzheimer disease-\nspeciﬁc conformation of hyperphosphorylated paired helical ﬁlament-Tau i s\npolyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquiti n conjugation.\nJ Biol Chem. (2006) 281:10825–38. doi: 10.1074/jbc.M512786200\n111. Mori H, Kondo J, Ihara Y. Ubiquitin is a component of\npaired helical ﬁlaments in Alzheimer’s disease. Science. (1987)\n235:1641–4. doi: 10.1126/science.3029875\n112. Perry G, Friedman R, Shaw G, Chau V. Ubiquitin is detected in\nneuroﬁbrillary tangles and senile plaque neurites of Alzheimer disease b rains.\nProc Natl Acad Sci USA. (1987) 84:3033–6. doi: 10.1073/pnas.84.9.3033\n113. Riederer IM, Schiﬀrin M, Kövari E, Bouras C, Riederer BM. Ubiq uitination\nand cysteine nitrosylation during aging and Alzheimer’s disease . Brain Res\nBull. (2009) 80:233–41. doi: 10.1016/j.brainresbull.2009.04.018\n114. Bancher C, Grundke-Iqbal I, Iqbal K, Fried V A, Smith HT, Wisn iewski\nHM. Abnormal phosphorylation of tau precedes ubiquitination in\nneuroﬁbrillary pathology of Alzheimer disease. Brain Res. (1991) 539:11–\n8. doi: 10.1016/0006-8993(91)90681-K\n115. García-Sierra F, Jarero-Basulto JJ, Kristoﬁkova Z, Majer E, B inder LI, Ripova\nD. Ubiquitin is associated with early truncation of tau protein at aspartic acid\n421 during the maturation of neuroﬁbrillary tangles in Alzheimer’s dise ase.\nBrain Pathol. (2012) 22:240–50. doi: 10.1111/j.1750-3639.2011.00525. x\n116. Iwatsubo T, Hasegawa M, Esaki Y, Ihara Y. Lack of ubiquiti n\nimmunoreactivities at both ends of neuropil threads possible bidirec tional\ngrowth of neuropil threads. Am J Pathol. (1992) 140:277–82.\n117. Dickey CA, Yue M, Lin WL, Dickson DW, Dunmore JH, Lee\nWC, et al. Deletion of the ubiquitin ligase CHIP leads to the\naccumulation, but not the aggregation, of both endogenous\nphospho- and caspase-3-cleaved tau species. J Neurosci. (2006)\n26:6985–96. doi: 10.1523/JNEUROSCI.0746-06.2006\n118. Desterro JMP , Thomson J, Hay RT. Ubch9 conjugates\nSUMO but not ubiquitin. FEBS Lett. (1997) 417:297–\n300. doi: 10.1016/S0014-5793(97)01305-7\n119. Gong L, Li B, Millas S, Yeh ETH. Molecular cloning and characteriz ation\nof human AOS1 and UBA2, components of the sentrin-activating enzy me\ncomplex. FEBS Lett. (1999) 448:185–9. doi: 10.1016/S0014-5793(99)00367-1\n120. Sarge KD, Park-Sarge OK. Sumoylation and human disease patho genesis.\nTrends Biochem Sci. (2009) 34:200–5. doi: 10.1016/j.tibs.2009.01.004\n121. Müller S, Ledl A, Schmidt D. SUMO: a regulator of gene\nexpression and genome integrity. Oncogene. (2004) 23:1998–\n2008. doi: 10.1038/sj.onc.1207415\n122. Jackson SP , Durocher D. Regulation of DNA damage responses by ubiquitin\nand SUMO. Mol Cell. (2013) 49:795–807. doi: 10.1016/j.molcel.2013.01.017\n123. Melchior F, Schergaut M, Pichler A. SUMO: ligases, isopeptid ases\nand nuclear pores. Trends Biochem Sci. (2003) 28:612–\n8. doi: 10.1016/j.tibs.2003.09.002\n124. Hickey CM, Wilson NR, Hochstrasser M. Function and regulation of SUMO\nproteases. Nat Rev Mol Cell Biol. (2012) 13:755–66. doi: 10.1038/nrm3478\n125. Henley JM, Carmichael RE, Wilkinson KA. Extranuclear SUMOylati on in\nneurons. Trends Neurosci. (2018) 41:198–210. doi: 10.1016/j.tins.2018.02.004\n126. Pountney DL, Huang Y, Burns RJ, Haan E, Thompson PD,\nBlumbergs PC, et al. SUMO-1 marks the nuclear inclusions in\nfamilial neuronal intranuclear inclusion disease. Exp Neurol. (2003)\n184:436–46. doi: 10.1016/j.expneurol.2003.07.004\n127. Wong MB, Goodwin J, Norazit A, Meedeniya ACB, Richter-\nLandsberg C, Gai WP , et al. SUMO-1 is associated with a subset o f\nlysosomes in glial protein aggregate diseases. Neurotox Res. (2013)\n23:1–21. doi: 10.1007/s12640-012-9358-z\n128. Luo H Bin, Xia YY, Shu XJ, Liu ZC, Feng Y, Liu XH, et al.\nSUMOylation at K340 inhibits tau degradation through deregulati ng its\nphosphorylation and ubiquitination. Proc Natl Acad Sci USA. (2014)\n111:16586–91. doi: 10.1073/pnas.1417548111\n129. Dorval V , Fraser PE. Small ubiquitin-like modiﬁer (SUMO) modi ﬁcation\nof natively unfolded proteins tau and α -synuclein. J Biol Chem. (2006)\n281:9919–24. doi: 10.1074/jbc.M510127200\n130. Hernandez I, Luna G, Rauch JN, Reis SA, Giroux M, Karch CM, et\nal. A farnesyltransferase inhibitor activates lysosomes and reduce s\ntau pathology in mice with tauopathy. Sci Transl Med. (2019)\n11:eaat3005. doi: 10.1126/scitranslmed.aat3005\n131. Avery OT, Macleod CM, McCarty M. Studies on the chemical natu re of\nthe substance inducing transformation of pneumococcal types: ind uction\nof transformation by a desoxyribonucleic acid fraction isolated fro m\npneumococcus type iii. J Exp Med. (1944) 79:137–58.\n132. MacCarty M, AVery OT. Studies on the chemical nature of the\nsubstance inducing transformation of pneumococcoal types: eﬀect of\ndesoxyribonuclease on the biological activit of the transforming substance.\nJ Exp Med. (1946) 83:89–96.\n133. Moore LD, Le T, Fan G. DNA methylation and its basic function .\nNeuropsychopharmacology. (2013) 38:23–38. doi: 10.1038/npp.2012.112\n134. Murn J, Shi Y. The winding path of protein methylation research:\nmilestones and new frontiers. Nat Rev Mol Cell Biol. (2017) 18:517–\n27. doi: 10.1038/nrm.2017.35\n135. Serre NBC, Alban C, Bourguignon J, Ravanel S. An outlook on lys ine\nmethylation of non-histone proteins in plants. J Exp Bot. (2018) 69:4569–\n81. doi: 10.1093/jxb/ery231\n136. Shi Y, Lan F, Matson C, Mulligan P , Whetstine JR, Cole PA, et a l. Histone\ndemethylation mediated by the nuclear amine oxidase homolog LSD1. Cell.\n(2004) 119:941–53. doi: 10.1016/j.cell.2004.12.012\n137. Lanouette S, Mongeon V , Figeys D, Couture JF. The functio nal\ndiversity of protein lysine methylation. Mol Syst Biol. (2014)\n10:724. doi: 10.1002/msb.134974\n138. Falnes P , Jakobsson ME, Davydova E, Ho A, Malecki J. Protein ly sine\nmethylation by seven- β -strand methyltransferases. Biochem J. (2016)\n473:1995–2009. doi: 10.1042/BCJ20160117\n139. Kontaxi C, Piccardo P , Gill AC. Lysine-directed post-transla tional\nmodiﬁcations of tau protein in Alzheimer’s disease and related\ntauopathies. Front Mol Biosci. (2017) 4:56. doi: 10.3389/fmolb.2017.\n00056\nFrontiers in Neurology | www.frontiersin.org 19 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\n140. Huseby CJ, Hoﬀman CN, Cooper GL, Cocuron JC, Alonso AP ,\nThomas SN, et al. Quantiﬁcation of tau protein lysine methylation\nin aging and Alzheimer’s disease. J Alzheimer’s Dis. (2019)\n71:979–91. doi: 10.3233/JAD-190604\n141. Funk KE, Thomas SN, Schafer KN, Cooper GL, Liao Z, Clark\nDJ, et al. Lysine methylation is an endogenous post-translational\nmodiﬁcation of tau protein in human brain and a modulator of\naggregation propensity. Biochem J. (2014) 462:77–88. doi: 10.1042/BJ201\n40372\n142. Sposito T, Preza E, Mahoney CJ, Setó-Salvia N, Ryan NS, Morris HR,\net al. Developmental regulation of tau splicing is disrupted in stem\ncell-derived neurons from frontotemporal dementia patients with the 10\n+ 16 splice-site mutation in MAPT. Hum Mol Genet. (2015) 24:5260–\n9. doi: 10.1093/hmg/ddv246\n143. Shental-Bechor D, Levy Y. Eﬀect of glycosylation on protein f olding: a\nclose look at thermodynamic stabilization. Proc Natl Acad Sci USA. (2008)\n105:8256–61. doi: 10.1073/pnas.0801340105\n144. Bell CG, Lowe R, Adams PD, Baccarelli AA, Beck S, Bell JT, et al. DN A\nmethylation aging clocks: challenges and recommendations. Genome Biol.\n(2019) 20:1–24. doi: 10.1186/s13059-019-1824-y\n145. Yang X, Qian K. Protein O-GlcNAcylation: emerging mechanisms a nd\nfunctions. Nat Rev Mol Cell Biol. (2017) 18:452–65. doi: 10.1038/nrm.2017.22\n146. Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in hea lth and\ndisease. Nat Rev Nephrol. (2019) 15:346–66. doi: 10.1038/s41581-019-0129-4\n147. Kim C-S, Park S, Kim J. The role of glycation in the pathogenesi s of aging\nand its prevention through herbal products and physical exercise. J Exerc\nNutr Biochem. (2017) 21:55–61. doi: 10.20463/jenb.2017.0027\n148. Liu L, Xu YX, Hirschberg CB. The role of nucleotide sugar transport ers\nin development of eukaryotes. Semin Cell Dev Biol. (2010) 21:600–\n8. doi: 10.1016/j.semcdb.2010.02.002\n149. Aebi M. N-linked protein glycosylation in the ER. Biochim Biophys Acta Mol\nCell Res. (2013) 1833:2430–7. doi: 10.1016/j.bbamcr.2013.04.001\n150. Sharma A, Vijayan M. Inﬂuence of glycosidic linkage on the na ture\nof carbohydrate binding in β -prism I fold lectins: an X-ray and\nmolecular dynamics investigation on banana lectin-carbohydrate complexes.\nGlycobiology. (2010) 21:23–33. doi: 10.1093/glycob/cwq128\n151. Spiro RG. Protein glycosylation: nature, distribution, enzyma tic formation,\nand disease implications of glycopeptide bonds. Glycobiology. (2002)\n12:43R− 56R. doi: 10.1093/glycob/12.4.43R\n152. Haltiwanger RS, Kelly WG, Roquemore EP , Blomberg MA, Dong\nL-YD, Kreppel L, et al. Glycosylation of nuclear and cytoplasmic\nproteins is ubiquitous and dynamic. Biochem Soc Trans. (1992) 20:264–\n9. doi: 10.1042/bst0200264\n153. Mitra N, Sinha S, Ramya TNC, Surolia A. N-linked oligosaccharid es as\noutﬁtters for glycoprotein folding, form and function. Trends Biochem Sci.\n(2006) 31:156–63. doi: 10.1016/j.tibs.2006.01.003\n154. O’Connor SE, Imperiali B. Modulation of protein structure and\nfunction by asparagine-linked glycosylation. Chem Biol. (1996)\n3:803–12. doi: 10.1016/S1074-5521(96)90064-2\n155. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX. O-\nGlcNAcylation regulates phosphorylation of tau: a mechanism\ninvolved in Alzheimer’s disease. Proc Natl Acad Sci USA. (2004)\n101:10804–9. doi: 10.1073/pnas.0400348101\n156. Cheng X, Cole RN, Zaia J, Hart GW. Alternative O-glycosylation/ O-\nphosphorylation of the murine estrogen receptor β . Biochemistry. (2000)\n39:11609–20. doi: 10.1021/bi000755i\n157. Comer FI, Hart GW. Reciprocity between O-GlcNAc and O-phosphat e on\nthe carboxyl terminal domain of RNA polymerase II. Biochemistry. (2001)\n40:7845–52. doi: 10.1021/bi0027480\n158. Yang WH, Kim JE, Nam HW, Ju JW, Kim HS, Kim YS, et al. Modiﬁcatio n of\np53 with O-linked N-acetylglucosamine regulates p53 activity and st ability.\nNat Cell Biol. (2006) 8:1074–83. doi: 10.1038/ncb1470\n159. Tarrant MK, Rho HS, Xie Z, Jiang YL, Gross C, Culhane JC, et al. Reg ulation\nof CK2 by phosphorylation and O-GlcNAcylation revealed by semisynthe sis.\nNat Chem Biol. (2012) 8:262–9. doi: 10.1038/nchembio.771\n160. Cole SL, Vassar R. The Alzheimer’s disease β -secretase enzyme, BACE1. Mol\nNeurodegener. (2007) 2:22. doi: 10.1186/1750-1326-2-22\n161. Kizuka Y, Kitazume S, Fujinawa R, Saito T, Iwata N, Saido T C, et\nal. An aberrant sugar modiﬁcation of BACE 1 blocks its lysosomal\ntargeting in A lzheimer’s disease. EMBO Mol Med. (2015) 7:175–\n89. doi: 10.15252/emmm.201404438\n162. Chun YS, Kwon OH, Chung S. O-GlcNAcylation of amyloid- β\nprecursor protein at threonine 576 residue regulates traﬃcking\nand processing. Biochem Biophys Res Commun. (2017) 490:486–\n91. doi: 10.1016/j.bbrc.2017.06.067\n163. Palmigiano A, Barone R, Sturiale L, Sanﬁlippo C, Bua RO, Romeo\nDA, et al. CSF N-glycoproteomics for early diagnosis in Alzheimer’s\ndisease. J Proteomics. (2016) 131:29–37. doi: 10.1016/j.jprot.2015.\n10.006\n164. Kizuka Y, Kitazume S, Taniguchi N. N-glycan and Alzheimer’s\ndisease. Biochim Biophys Acta Gen Subj. (2017) 1861:2447–\n54. doi: 10.1016/j.bbagen.2017.04.012\n165. Gong C-X, Liu F, Iqbal K. O-GlcNAcylation: a regulator of tau\npathology and neurodegeneration. Alzheimer’s Dement. (2016) 12:1078–\n89. doi: 10.1016/j.jalz.2016.02.011\n166. Shane Arnold C, Johnson GVW, Cole RN, Dong DLY, Lee M, Hart\nGW. The microtubule-associated protein tau is extensively modiﬁed\nwith O- linked N-acetylglucosamine. J Biol Chem. (1996) 271:28741–\n4. doi: 10.1074/jbc.271.46.28741\n167. Wang JZ, Grundke-Iqbal I, Iqbal K. Glycosylation of microtub ule-associated\nprotein tau: an abnormal posttranslational modiﬁcation in Alzheimer’ s\ndisease. Nat Med. (1996) 2:871–5. doi: 10.1038/nm0896-871\n168. Sato Y, Naito Y, Grundke-Iqbal I, Iqbal K, Endo T. Analysis of\nN-glycans of pathological tau: Possible occurrence of aberrant\nprocessing of tau in Alzheimer’s disease. FEBS Lett. (2001)\n496:152–60. doi: 10.1016/S0014-5793(01)02421-8\n169. Liu F, Zaidi T, Iqbal K, Grundke-Iqbal I, Merkle RK, Gong CX. R ole of\nglycosylation in hyperphosphorylation of tau in Alzheimer’s disease. FEBS\nLett. (2002) 512:101–6. doi: 10.1016/S0014-5793(02)02228-7\n170. Robertson LA, Moya KL, Breen KC. The potential role of tau protei n\nO-glycosylation in Alzheimer’s disease. J Alzheimer’s Dis. (2004) 6:489–\n95. doi: 10.3233/JAD-2004-6505\n171. Yuzwa SA, Shan X, MacAuley MS, Clark T, Skorobogatko Y, Vosselle r K, et\nal. Increasing O-GlcNAc slows neurodegeneration and stabilizes ta u against\naggregation. Nat Chem Biol. (2012) 8:393–9. doi: 10.1038/nchembio.797\n172. Yuzwa SA, Yadav AK, Skorobogatko Y, Clark T, Vosseller K, Voca dlo\nDJ. Mapping O-GlcNAc modiﬁcation sites on tau and generation of\na site-speciﬁc O-GlcNAc tau antibody. Amino Acids. (2011) 40:857–\n68. doi: 10.1007/s00726-010-0705-1\n173. Smet-Nocca C, Broncel M, Wieruszeski JM, Tokarski C, Hanou lle X,\nLeroy A, et al. Identiﬁcation of O-GlcNAc sites within peptides of the tau\nprotein and their impact on phosphorylation. Mol Biosyst. (2011) 7:1420–\n9. doi: 10.1039/c0mb00337a\n174. Lefebvre T, Ferreira S, Dupont-Wallois L, Bussière T, Dupire MJ, De lacourte\nA, et al. Evidence of a balance between phosphorylation and O-GlcNAc\nglycosylation of tau proteins - a role in nuclear localization. Biochim Biophys\nActa Gen Subj. (2003) 1619:167–76. doi: 10.1016/S0304-4165(02)00477-4\n175. Yuzwa SA, Cheung AH, Okon M, McIntosh LP , Vocadlo DJ. O-GlcN Ac\nmodiﬁcation of tau directly inhibits its aggregation without pert urbing the\nconformational properties of tau monomers. J Mol Biol. (2014) 426:1736–\n52. doi: 10.1016/j.jmb.2014.01.004\n176. Yu CH, Si T, Wu WH, Hu J, Du JT, Zhao YF, et al. O-GlcNAcylation\nmodulates the self-aggregation ability of the fourth microtubule-\nbinding repeat of tau. Biochem Biophys Res Commun. (2008)\n375:59–62. doi: 10.1016/j.bbrc.2008.07.101\n177. Schedin-Weiss S, Winblad B, Tjernberg LO. The role of protein g lycosylation\nin Alzheimer disease. FEBS J. (2014) 281:46–62. doi: 10.1111/febs.12590\n178. Liu F, Zaidi T, Iqbal K, Grundke-Iqbal I, Gong CX. Aberrant\nglycosylation modulates phosphorylation of tau by protein kinase A and\ndephosphorylation of tau by protein phosphatase 2A and 5. Neuroscience.\n(2002) 115:829–37. doi: 10.1016/S0306-4522(02)00510-9\n179. Cho S-J, Roman G, Yeboah F, Konishi Y. The road to advanced g lycation\nend products: a mechanistic perspective. Curr Med Chem. (2007) 14:1653–\n71. doi: 10.2174/092986707780830989\nFrontiers in Neurology | www.frontiersin.org 20 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\n180. Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fuj ii N,\net al. Advanced glycation end products in Alzheimer’s disease\nand other neurodegenerative diseases. Am J Pathol. (1998)\n153:1149–55. doi: 10.1016/S0002-9440(10)65659-3\n181. Yamagishi SI, Nakamura N, Matsui T. Glycation and cardiovasc ular disease\nin diabetes: a perspective on the concept of metabolic memory. J Diabetes.\n(2017) 9:141–8. doi: 10.1111/1753-0407.12475\n182. Simm A, Müller B, Nass N, Hofmann B, Bushnaq H, Silber RE, et al.\nProtein glycation - between tissue aging and protection. Exp Gerontol. (2015)\n68:71–5. doi: 10.1016/j.exger.2014.12.013\n183. Luth H-JL, Ogunlade V , Kuhla BB, Kientsch-Engel R, Stahl P , Webster J, et al.\nAge-and stage-dependent accumulation of advanced glycation en d products\nin intracellular deposits in normal and Alzheimer’s disease brains. Cereb\nCortex. (2005) 15:211–20. doi: 10.1093/cercor/bhh123\n184. Chaudhuri J, Bains Y, Guha S, Kahn A, Hall D, Bose N, et al.\nThe role of advanced glycation end products in aging and metabolic\ndiseases: bridging association and causality. Cell Metab. (2018) 28:337–\n52. doi: 10.1016/j.cmet.2018.08.014\n185. Ramasamy R, Vannucci SJ, Yan SS Du, Herold K, Yan SF, Schmidt\nAM. Advanced glycation end products and RAGE: a common thread in\naging, diabetes, neurodegeneration, and inﬂammation. Glycobiology. (2005)\n15:16R− 28R. doi: 10.1093/glycob/cwi053\n186. Nacharaju P , Ko L, Yen S-HC. Characterization of in\nvitro glycation sites of tau. J Neurochem. (1997) 69:1709–\n19. doi: 10.1046/j.1471-4159.1997.69041709.x\n187. Liu K, Liu Y, Li L, Qin P , Iqbal J, Deng Y, et al. Glycation\nalter the process of tau phosphorylation to change tau isoforms\naggregation property. Biochim Biophys Acta Mol Basis Dis. (2016) 1862:192–\n201. doi: 10.1016/j.bbadis.2015.12.002\n188. Ko LW, Ko EC, Nacharaju P , Liu WK, Chang E, Kenessey A, et al. An\nimmunochemical study on tau glycation in paired helical ﬁlaments. Brain\nRes. (1999) 830:301–13. doi: 10.1016/S0006-8993(99)01415-8\n189. Ledesma MD, Medina M, Avila J. The in vitro formation of recombinant τ\npolymers - eﬀect of phosphorylation and glycation. Mol Chem Neuropathol.\n(1996) 27:249–58. doi: 10.1007/BF02815107\n190. Smith MA, Siedlak SL, Richey PL, Nagaraj RH, Elhammer A,\nPerry G. Quantitative solubilization and analysis of insoluble\npaired helical ﬁlaments from Alzheimer disease. Brain Res. (1996)\n717:99–108. doi: 10.1016/0006-8993(95)01473-X\n191. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, et al. Glyca ted tau\nprotein in Alzheimer disease: a mechanism for induction of oxidan t stress.\nProc Natl Acad Sci USA. (1994) 91:7787–91. doi: 10.1073/pnas.91.16.7787\n192. Quinn JP , Corbett NJ, Kellett KAB, Hooper NM. Tau proteolysis in the\npathogenesis of tauopathies: neurotoxic fragments and novel bio markers. J\nAlzheimer’s Dis.(2018) 63:13–33. doi: 10.3233/JAD-170959\n193. van Opdenbosch N, Lamkanﬁ M. Caspases in cell death, inﬂammati on, and\ndisease. Immunity. (2019) 50:1352–64. doi: 10.1016/j.immuni.2019.05.020\n194. McIlwain DR, Berger T, Mak TW. Caspase functions in cell\ndeath and disease. Cold Spring Harb Perspect Biol. (2013)\n5:ea008656. doi: 10.1101/cshperspect.a008656\n195. Chesser AS, Pritchard SM, Johnson GVW. Tau clearance mechani sms and\ntheir possible role in the pathogenesis of Alzheimer disease. Front Neurol.\n(2013) 4:122. doi: 10.3389/fneur.2013.00122\n196. Fasulo L, Visintin M, Novak M, Cattaneo A. Tau truncation i n Alzheimer’s\ndisease: expression of a fragment encompassing PHF core. Alzheimer’s Rep.\n(1998) 1:25–32.\n197. Novák M. Truncated tau protein as a new marker for Alzheimer’s di sease.\nActa Virol. (1994) 38:173–89.\n198. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet\nAL, et al. Caspase cleavage of tau: linking amyloid and neuroﬁbrillary\ntangles in Alzheimer’s disease. Proc Natl Acad Sci USA. (2003) 100:10032–\n7. doi: 10.1073/pnas.1630428100\n199. Paholikova K, Salingova B, Opattova A, Skrabana R, Majerova P , Zilka\nN, et al. N-terminal truncation of microtubule associated protein tau\ndysregulates its cellular localization. J Alzheimer’s Dis. (2015) 43:915–\n26. doi: 10.3233/JAD-140996\n200. Corsetti V , Florenzano F, Atlante A, Bobba A, Ciotti MT, Nat ale F, et al.\nNH 2-truncated human tau induces deregulated mitophagy in neurons b y\naberrant recruitment of Parkin and UCHL-1: implications in Alzheimer’s\ndisease. Hum Mol Genet. (2015) 24:3058–81. doi: 10.1093/hmg/ddv059\n201. Chung CW, Song YH, Kim IK, Yoon WJ, Ryu BR, Jo DG, et al. Proapopt otic\neﬀects of tau cleavage product generated by caspase-3. Neurobiol Dis. (2001)\n8:162–72. doi: 10.1006/nbdi.2000.0335\n202. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP , et\nal. Caspase-cleavage of tau is an early event in Alzheimer disease ta ngle\npathology. J Clin Invest. (2004) 114:121–30. doi: 10.1172/JCI200420640\n203. Rohn TT, Rissman RA, Head E, Cotman CW. Caspase activation\nin the Alzheimer’s disease brain: tortuous and torturous. Drug\nNews Perspect. (2002) 15:549–57. doi: 10.1358/dnp.2002.15.9.74\n0233\n204. Su JH, Zhao M, Anderson AJ, Srinivasan A, Cotman CW.\nActivated caspase-3 expression in Alzheimer’s and aged control\nbrain: correlation with Alzheimer pathology. Brain Res. (2001)\n898:350–7. doi: 10.1016/S0006-8993(01)02018-2\n205. Guo H, Albrecht S, Bourdeau M, Petzke T, Bergeron C, LeBlanc AC. Active\ncaspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques,\nand neuroﬁbrillary tangles of Alzheimer’s disease. Am J Pathol. (2004)\n165:523–31. doi: 10.1016/S0002-9440(10)63317-2\n206. Matthews-Roberson TA, Quintanilla RA, Ding H, Johnson GVW .\nImmortalized cortical neurons expressing caspase-cleaved tau are sens itized\nto endoplasmic reticulum stress induced cell death. Brain Res. (2008)\n1234:206–12. doi: 10.1016/j.brainres.2008.07.111\n207. Quintanilla RA, Matthews-Roberson TA, Dolan PJ, Johnsion\nGVW. Caspase-cleaved tau expression induces mitochondrial\ndysfunction in immortalized cortical neurons: implications for\nthe pathogenesis of alzheimer disease. J Biol Chem. (2009)\n284:18754–66. doi: 10.1074/jbc.M808908200\n208. De Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spi res-Jones\nTL, et al. Caspase activation precedes and leads to tangles. Nature. (2010)\n464:1201–4. doi: 10.1038/nature08890\n209. Suzuki K, Hata S, Kawabata Y, Sorimachi H. Structure, activat ion,\nand biology of calpain. Diabetes. (2004). 53(Suppl.):S12–\n8. doi: 10.2337/diabetes.53.2007.S12\n210. Park SY, Ferreira A. The generation of a 17 kDa neurotoxic\nfragment: an alternative mechanism by which tau mediates\nβ -amyloid-induced neurodegeneration. J Neurosci. (2005)\n25:5365–75. doi: 10.1523/JNEUROSCI.1125-05.2005\n211. Liu MC, Kobeissy F, Zheng W, Zhang Z, Hayes RL, Wang KKW.\nDual vulnerability of tau to calpains and caspase-3 proteolysis under\nneurotoxic and neurodegenerative conditions. ASN Neuro. (2011) 3:25–\n36. doi: 10.1042/AN20100012\n212. Chen HH, Liu P , Auger P , Lee SH, Adolfsson O, Rey-Bellet L, et al. C alpain-\nmediated tau fragmentation is altered in Alzheimer’s disease progress ion. Sci\nRep. (2018) 8:16725. doi: 10.1038/s41598-018-35130-y\n213. Reinecke JB, deVos SL, McGrath JP , Shepard AM, Goncharoﬀ DK, Tait DN,\net al. Implicating calpain in tau-mediated toxicity in vivo. PLoS ONE. (2011)\n6:e23865. doi: 10.1371/journal.pone.0023865\n214. Olesen OF. Proteolytic degradation of microtubule-associate d\nprotein τ by thrombin. Biochem Biophys Res Commun. (1994)\n201:716–21. doi: 10.1006/bbrc.1994.1759\n215. Khlistunova I, Biernat J, Wang Y, Pickhardt M, Von Bergen M, Gazova Z,\net al. Inducible expression of tau repeat domain in cell models of tauopat hy:\nAggregation is toxic to cells but can be reversed by inhibitor drug s. J Biol\nChem. (2006) 281:1205–14. doi: 10.1074/jbc.M507753200\n216. Arai T, Guo JP , McGeer PL. Proteolysis of non-phosphorylated\nand phosphorylated tau by thrombin. J Biol Chem. (2005)\n280:5145–53. doi: 10.1074/jbc.M409234200\n217. Suo Z, Wu M, Citron BA, Palazzo RE, Festoﬀ BW. Rapid tau aggreg ation\nand delayed hippocampal neuronal death induced by persistent thrombi n\nsignaling. J Biol Chem. (2003) 278:37681–9. doi: 10.1074/jbc.M301406200\n218. Schönichen A, Webb BA, Jacobson MP , Barber DL. Consideri ng\nprotonation as a posttranslational modiﬁcation regulating\nprotein structure and function. Annu Rev Biophys. (2013)\n42:289–314. doi: 10.1146/annurev-biophys-050511-102349\n219. Harguindey S, Reshkin S, Orive G, Luis Arranz J, Anitua E. Gro wth\nand trophic factors, pH and the Na + /H+ exchanger in Alzheimers\nFrontiers in Neurology | www.frontiersin.org 21 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\ndisease, other neurodegenerative diseases and cancer: new th erapeutic\npossibilities and potential dangers. Curr Alzheimer Res. (2007) 4:53–\n65. doi: 10.2174/156720507779939841\n220. Syntichaki P , Samara C, Tavernarakis N. The vacuolar H + -ATPase mediates\nintracellular acidiﬁcation required for neurodegeneration in C. elegans. Curr\nBiol. (2005) 15:1249–54. doi: 10.1016/j.cub.2005.05.057\n221. Charafeddine RA, Cortopassi WA, Lak P , Tan R, McKenney RJ, J acobson MP ,\net al. Tau repeat regions contain conserved histidine residues th at modulate\nmicrotubule-binding in response to changes in pH downloaded from. J Biol\nChem. (2019) 294:8779–90. doi: 10.1074/jbc.RA118.007004\n222. Chung HS, Wang SB, Venkatraman V , Murray CI, van Eyk\nJE. Cysteine oxidative posttranslational modiﬁcations: emergi ng\nregulation in the cardiovascular system. Circ Res. (2013)\n112:382–92. doi: 10.1161/CIRCRESAHA.112.268680\n223. Reeg S, Grune T. Protein oxidation in aging: does it play a\nrole in aging progression? Antioxidants Redox Signal. (2015)\n23:239–55. doi: 10.1089/ars.2014.6062\n224. Schweers O, Mandelkow EM, Biernat J, Mandelkow E. Oxidatio n of cysteine-\n322 in the repeat domain of microtubule-associated protein τ controls the in\nvitro assembly of paired helical ﬁlaments. Proc Natl Acad Sci USA. (1995)\n92:8463–7. doi: 10.1073/pnas.92.18.8463\n225. Reynolds MR, Berry RW, Binder LI. Nitration in neurodegenerat ion:\ndeciphering the “hows” “nYs.” Biochemistry. (2007) 46:7325–\n36. doi: 10.1021/bi700430y\n226. Tedeschi G, Cappelletti G, Nonnis S, Taverna F, Negri A, Ronchi C, et al.\nTyrosine nitration is a novel post-translational modiﬁcation occ urring on\nthe neural intermediate ﬁlament protein peripherin. Neurochem Res. (2007)\n32:433–41. doi: 10.1007/s11064-006-9244-2\n227. Radi R. Protein tyrosine nitration: biochemical mechanisms\nand structural basis of functional eﬀects. Acc Chem Res. (2013)\n46:550–9. doi: 10.1021/ar300234c\n228. Reyes JF, Fu Y, Vana L, Kanaan NM, Binder LI. Tyrosine nitra tion within\nthe proline-rich region of tau in Alzheimer’s disease. Am J Pathol. (2011)\n178:2275–85. doi: 10.1016/j.ajpath.2011.01.030\n229. Reyes JF, Geula C, Vana L, Binder LI. Selective tau tyrosine\nnitration in non-AD tauopathies. Acta Neuropathol. (2012)\n123:119–32. doi: 10.1007/s00401-011-0898-8\n230. Reyes JF, Reynolds MR, Horowitz PM, Fu Y, Guillozet-Bongaarts AL,\nBerry R, et al. A possible link between astrocyte activation and\ntau nitration in Alzheimer’s disease. Neurobiol Dis. (2008) 31:198–\n208. doi: 10.1016/j.nbd.2008.04.005\n231. Hipp MS, Kasturi P , Hartl FU. The proteostasis network\nand its decline in ageing. Nat Rev Mol Cell Biol. (2019)\n20:421–35. doi: 10.1038/s41580-019-0101-y\n232. Aoki K, Yoshida K. “Biological Consequences of Priming Pho sphorylation in\nCancer Development, ” inProtein Phosphorylation (InTech).\n233. Butler VJ, Salazar DA, Soriano-Castell D, Alves-Ferreira M, Den nissen FJA,\nVohra M, et al. Tau/MAPT disease-associated variant A152T alter s tau\nfunction and toxicity via impaired retrograde axonal transport. Hum Mol\nGenet. (2019) 28:1498–514. doi: 10.1093/hmg/ddy442\n234. Kirchner P , Bourdenx M, Madrigal-Matute J, Tiano S, Diaz A, Bartholdy BA,\net al. Proteome-wide analysis of chaperone-mediated autophagy targ eting\nmotifs. PLoS Biol. (2019) 17:e3000301. doi: 10.1371/journal.pbio.3000301\n235. Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K,\nKhoshnan A, et al. IKK phosphorylates Huntingtin and targets it\nfor degradation by the proteasome and lysosome. J Cell Biol. (2009)\n187:1083–1099. doi: 10.1083/jcb.200909067\n236. Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H, et al. Acetylation tar gets\nthe M2 isoform of pyruvate kinase for degradation through chaperone -\nmediated autophagy and promotes tumor growth. Mol Cell. (2011) 42:719–\n30. doi: 10.1016/j.molcel.2011.04.025\n237. Jung T, Catalgol B, Grune T. The proteasomal system. Mol Aspects Med.\n(2009) 30:191–296. doi: 10.1016/j.mam.2009.04.001\n238. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolyt ic\npathway: destruction for the sake of construction. Physiol Rev. (2002)\n82:373–428. doi: 10.1152/physrev.00027.2001\n239. Murata S, Yashiroda H, Tanaka K. Molecular mechanisms of proteaso me\nassembly. Nat Rev Mol Cell Biol. (2009) 10:104–15. doi: 10.1038/nrm2630\n240. Coux O, Tanaka K, Goldberg AL. Structure and Functions\nof the 20S and 26S proteasomes. Annu Rev Biochem. (1996)\n65:801–47. doi: 10.1146/annurev.bi.65.070196.004101\n241. Jariel-Encontre I, Bossis G, Piechaczyk M. Ubiquitin-ind ependent\ndegradation of proteins by the proteasome. BBA Rev Cancer. (2008)\n1786:153–77. doi: 10.1016/j.bbcan.2008.05.004\n242. Wang Y, Mandelkow E. Degradation of tau protein by autophagy\nand proteasomal pathways. Biochem Soc Trans. (2012) 40:644–\n52. doi: 10.1042/BST20120071\n243. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J,\net al. The high-aﬃnity HSP90-CHIP complex recognizes and selectively\ndegrades phosphorylated tau client proteins. J Clin Invest. (2007) 117:648–\n58. doi: 10.1172/JCI29715\n244. Holt LJ. Regulatory modules: Coupling protein stability to\nphopshoregulation during cell division. FEBS Lett. (2012)\n586:2773–7. doi: 10.1016/j.febslet.2012.05.045\n245. Engmann O, Giese KP. Crosstalk between Cdk5 and GSK3 β :\nimplications for Alzheimer’s disease. Front Mol Neurosci. (2009)\n2:9. doi: 10.3389/neuro.02.002.2009\n246. Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition by pai red helical\nﬁlament-tau in brains of patients with Alzheimer’s disease. J Neurochem.\n(2003) 85:115–22. doi: 10.1046/j.1471-4159.2003.01642. x\n247. Keller JN, Hanni KB, Markesbery WR. Impaired proteasome\nfunction in Alzheimer’s disease. J Neurochem. (2000) 75:436–\n9. doi: 10.1046/j.1471-4159.2000.0750436.x\n248. López Salon M, Morelli L, Castaño EM, Soto EF, Pasquini JM. Def ective\nubiquitination of cerebral proteins in Alzheimer’s disease. J Neurosci\nRes. (2000) 62:302–10. doi: 10.1002/1097-4547(20001015)62:2 <302::AID-\nJNR15>3.0.CO;2-L\n249. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-\nproteasome system by protein aggregation. Science. (2001) 292:1552–\n5. doi: 10.1126/science.292.5521.1552\n250. Goldberg AL. Protein degradation and protection against misf olded or\ndamaged proteins. Nature. (2003) 426:895–9. doi: 10.1038/nature02263\n251. Caballero B, Wang Y, Diaz A, Tasset I, Juste YR, Stiller B, et al. Interplay of\npathogenic forms of human tau with diﬀerent autophagic pathways. Aging\nCell. (2018) 17:e12692. doi: 10.1111/acel.12692\n252. Wang Y, Martinez-Vicente M, Krüger U, Kaushik S, Wong E,\nMandelkow EM, et al. Tau fragmentation, aggregation and clearance:\nthe dual role of lysosomal processing. Hum Mol Genet. (2009)\n18:4153–70. doi: 10.1093/hmg/ddp367\n253. Hamano T, Gendron TF, Causevic E, Yen SH, Lin WL, Isidoro C,\net al. Autophagic-lysosomal perturbation enhances tau aggregatio n in\ntransfectants with induced wild-type tau expression. Eur J Neurosci. (2008)\n27:1119–30. doi: 10.1111/j.1460-9568.2008.06084.x\n254. Wang Y, Martinez-Vicente M, Krüger U, Kaushik S, Wong E, Ma ndelkow\nEM, et al. Synergy and antagonism of macroautophagy and chaperone-\nmediated autophagy in a cell model of pathological tau aggregation.\nAutophagy. (2010) 6:182–3. doi: 10.4161/auto.6.1.10815\n255. Kim SI, Lee WK, Kang SS, Lee SY, Jeong MJ, Lee HJ, et al. Suppress ion of\nautophagy and activation of glycogen synthase kinase 3beta fa cilitate the\naggregate formation of tau. Korean J Physiol Pharmacol. (2011) 15:107–\n14. doi: 10.4196/kjpp.2011.15.2.107\n256. Sahu R, Kaushik S, Clement CC, Cannizzo ES, Scharf B, Follenz i A, et al.\nMicroautophagy of cytosolic proteins by late endosomes. Dev Cell. (2011)\n20:131–9. doi: 10.1016/j.devcel.2010.12.003\n257. Gorantla NV , Chinnathambi S. Autophagic pathways to clear the\ntau aggregates in Alzheimer’s disease. Cell Mol Neurobiol . (2020).\ndoi: 10.1007/s10571-020-00897-0. [Epub ahead of print].\n258. Vaz-Silva J, Gomes P , Jin Q, Zhu M, Zhuravleva V , Quintremil\nS, et al. Endolysosomal degradation of tau and its role in\nglucocorticoid-driven hippocampal malfunction. EMBO J. (2018)\n37:e99084. doi: 10.15252/embj.201899084\n259. Yorimitsu T, Klionsky DJ. Autophagy: molecular machinery for self -eating.\nCell Death Diﬀer. (2005) 12:1542–52. doi: 10.1038/sj.cdd.4401765\n260. Dolan PJ, Johnson GVW. A caspase cleaved form of tau is preferent ially\ndegraded through the autophagy pathway. J Biol Chem. (2010) 285:21978–\n87. doi: 10.1074/jbc.M110.110940\nFrontiers in Neurology | www.frontiersin.org 22 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\n261. Rohn TT, Wirawan E, Brown RJ, Harris JR, Masliah E,\nVandenabeele P. Depletion of Beclin-1 due to proteolytic cleavage\nby caspases in the Alzheimer’s disease brain. Neurobiol Dis. (2011)\n43:68–78. doi: 10.1016/j.nbd.2010.11.003\n262. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoﬀ C, Cataldo A, et a l.\nExtensive involvement of autophagy in Alzheimer disease: an immuno -\nelectron microscopy study. J Neuropathol Exp Neurol. (2005) 64:113–\n22. doi: 10.1093/jnen/64.2.113\n263. Piras A, Collin L, Grüninger F, Graﬀ C, Rönnbäck A. Autophagic a nd\nlysosomal defects in human tauopathies: analysis of post-mortem brai n\nfrom patients with familial Alzheimer disease, corticobasal degen eration\nand progressive supranuclear palsy. Acta Neuropathol Commun. (2016)\n4:22. doi: 10.1186/s40478-016-0292-9\n264. Caccamo A, Magrì A, Medina DX, Wisely E V , López-Aranda MF, Silva AJ,\net al. mTOR regulates tau phosphorylation and degradation: implication s\nfor Alzheimer’s disease and other tauopathies. Aging Cell. (2013) 12:370–\n80. doi: 10.1111/acel.12057\n265. Ikeda K, Akiyama H, Arai T, Kondo H, Haga C, Tsuchiya K, et al. Ne urons\ncontaining Alz-50-immunoreactive granules around the cerebral infa rction:\nevidence for the lysosomal degradation of altered tau in human brain ?\nNeurosci Lett. (2000) 284:187–9. doi: 10.1016/S0304-3940(00)01009-0\n266. Ikeda K, Akiyama H, Arai T, Kondo H, Haga C, Iritani S, et\nal. Alz-50/Gallyas-positive lysosome-like intraneuronal granules\nin Alzheimer’s disease and control brains. Neurosci Lett. (1998)\n258:113–6. doi: 10.1016/S0304-3940(98)00867-2\n267. D’Agostino C, Nogalska A, Cacciottolo M, King Engel W, Ask anas V.\nAbnormalities of NBR1, a novel autophagy-associated protein, in mu scle\nﬁbers of sporadic inclusion-body myositis. Acta Neuropathol. (2011)\n122:627–36. doi: 10.1007/s00401-011-0874-3\n268. Majid T, Ali YO, Venkitaramani DV , Jang MK, Lu HC, Pautler RG. in vivo\naxonal transport deﬁcits in a mouse model of fronto-temporal dementia.\nNeuroImage Clin. (2014) 4:711–7. doi: 10.1016/j.nicl.2014.02.005\n269. Butzlaﬀ M, Hannan SB, Karsten P , Lenz S, Ng J, Voßfeldt H, et\nal. Impaired retrograde transport by the dynein/dynactin complex\ncontributes to tau-induced toxicity. Hum Mol Genet. (2015) 24:3623–\n37. doi: 10.1093/hmg/ddv107\n270. Young ZT, Mok SA, Gestwicki JE. Therapeutic strategies for\nrestoring tau homeostasis. Cold Spring Harb Perspect Med. (2018)\n8:ea024612. doi: 10.1101/cshperspect.a024612\n271. Schweers O, Schonbrunn-Hanebeck E, Man A, Mandelkows E. S tructural\nstudies of tau protein and Alzheimer paired helical ﬁlaments show no\nevidence for beta-structure. J Biol Chem. (1994) 269:24290–7.\n272. Mukrasch MD, Bibow S, Korukottu J, Jeganathan S, Biernat J, Griesinger C,\net al. Structural polymorphism of 441-residue tau at single residue resolu tion.\nPLoS Biol. (2009) 7:e1000034. doi: 10.1371/journal.pbio.1000034\n273. Jeganathan S, Von Bergen M, Brutlach H, Steinhoﬀ HJ, Mandelko w E.\nGlobal hairpin folding of tau in solution. Biochemistry. (2006) 45:2283–\n93. doi: 10.1021/bi0521543\n274. Dobson CM. Protein misfolding, evolution and disease. Trends Biochem Sci.\n(1999) 24:329–32. doi: 10.1016/S0968-0004(99)01445-0\n275. Dobson CM. Protein folding and misfolding. Nature. (2003) 426:884–\n90. doi: 10.1038/nature02261\n276. Knowles TPJ, Vendruscolo M, Dobson CM. The amyloid state and i ts\nassociation with protein misfolding diseases. Nat Rev Mol Cell Biol. (2014)\n15:384–96. doi: 10.1038/nrm3810\n277. Chiti F, Dobson CM. Protein misfolding, amyloid formation, and human\ndisease: a summary of progress over the last decade. Annu Rev Biochem.\n(2017) 86:27–68. doi: 10.1146/annurev-biochem-061516-045 115\n278. Fitzpatrick AW, Saibil HR. Cryo-EM of amyloid ﬁbrils and\ncellular aggregates. Curr Opin Struct Biol. (2019) 58:34–\n42. doi: 10.1016/j.sbi.2019.05.003\n279. Scheres SH, Zhang W, Falcon B, Goedert M. Cryo-EM\nstructures of tau ﬁlaments. Curr Opin Struct Biol. (2020)\n64:17–25. doi: 10.1016/j.sbi.2020.05.011\n280. Falcon B, Zhang W, Murzin AG, Murshudov G, Garringer HJ, Vidal\nR, et al. Structures of ﬁlaments from Pick’s disease reveal a novel\ntau protein fold. Nature. (2018) 561:137–40. doi: 10.1038/s41586-018-\n0454-y\n281. Fitzpatrick AWP , Falcon B, He S, Murzin AG, Murshudov G, Garring er HJ,\net al. Cryo-EM structures of tau ﬁlaments from Alzheimer’s disease. Nature.\n(2017) 547:185–90. doi: 10.1038/nature23002\n282. Arakhamia T, Lee CE, Carlomagno Y, Duong DM, Kundinger\nSR, Wang K, et al. Posttranslational modiﬁcations mediate\nthe structural diversity of tauopathy strains. Cell. (2020)\n180:633–44.e12. doi: 10.1016/j.cell.2020.01.027\n283. Falcon B, Zivanov J, Zhang W, Murzin AG, Garringer HJ, Vidal R, et al. Novel\ntau ﬁlament fold in chronic traumatic encephalopathy encloses hydrophob ic\nmolecules. Nature. (2019) 568:420–3. doi: 10.1038/s41586-019-1\n026-5\n284. Zhang W, Tarutani A, Newell KL, Murzin AG, Matsubara T, Falcon B,\net al. Novel tau ﬁlament fold in corticobasal degeneration. Nature. (2020)\n580:283–7. doi: 10.1038/s41586-020-2043-0\n285. Fontaine SN, Sabbagh JJ, Baker J, Martinez-Licha CR, Darli ng A, Dickey CA.\nCellular factors modulating the mechanism of tau protein aggregation . Cell\nMol Life Sci. (2015) 72:1863–79. doi: 10.1007/s00018-015-1839-9\n286. Wille H, Drewes G, Biernat J, Mandelkow EM, Mandelkow E. Alzheimer -\nlike paired helical ﬁlaments and antiparallel dimers formed from\nmicrotubule-associated protein tau in vitro . J Cell Biol. (1992) 118:573–\n84. doi: 10.1083/jcb.118.3.573\n287. Crowther RA, Olesen OF, Smith MJ, Jakes R, Goedert M. Assembly o f\nAlzheimer-like ﬁlaments from full-length tau protein. FEMS Lett. (1994)\n337:135–8. doi: 10.1016/0014-5793(94)80260-2\n288. Wilson DM, Binder LI. Polymerization of microtubule-associat ed protein\ntau under near-physiological conditions. J Biol Chem. (1995) 270:24306–\n14. doi: 10.1074/jbc.270.41.24306\n289. Reynolds MR, Reyes JF, Fu Y, Bigio EH, Guillozet-Bongaarts AL , Berry\nRW, et al. Tau nitration occurs at tyrosine 29 in the ﬁbrillar lesions of\nAlzheimer’s disease and other tauopathies. J Neurosci. (2006) 26:10636–\n45. doi: 10.1523/JNEUROSCI.2143-06.2006\n290. Trzeciakiewicz H, Tseng JH, Wander CM, Madden V , Tripathy A, Y uan\nCX, et al. A dual pathogenic mechanism links tau acetylation to sporad ic\ntauopathy. Sci Rep. (2017) 7:44102. doi: 10.1038/srep44102\n291. Avila J. Tau aggregation into ﬁbrillar polymers: taupathies. FEBS Lett. (2000)\n476:89–92. doi: 10.1016/S0014-5793(00)01676-8\n292. Sinha S, Lopes DHJ, Du Z, Pang ES, Shanmugam A, Lomakin A, et al. Lysine-\nspeciﬁc molecular tweezers are broad-spectrum inhibitors of assembly\nand toxicity of amyloid proteins. J Am Chem Soc. (2011) 133:16958–\n69. doi: 10.1021/ja206279b\n293. West LE, Gozani O. Regulation of p53 function by lysine methy lation.\nEpigenomics. (2011) 3:361–9. doi: 10.2217/epi.11.21\n294. Bhattacharya K, Rank KB, Evans DB, Sharma SK. Role of cystein e-\n291 and cysteine-322 in the polymerization of human tau into\nAlzheimer-like ﬁlaments. Biochem Biophys Res Commun. (2001)\n285:20–6. doi: 10.1006/bbrc.2001.5116\n295. Necula M, Kuret J. Pseudophosphorylation and glycation of tau pro tein\nenhance but do not trigger ﬁbrillization in vitro . J Biol Chem. (2004)\n279:49694–703. doi: 10.1074/jbc.M405527200\n296. Brister MA, Pandey AK, Bielska AA, Zondlo NJ. OGlcNAcylation and\nphosphorylation have opposing structural eﬀects in tau: phosphothreon ine\ninduces particular conformational order. J Am Chem Soc. (2014) 136:3803–\n16. doi: 10.1021/ja407156m\n297. Lothrop AP , Torres MP , Fuchs SM. Deciphering post-\ntranslational modiﬁcation codes. FEBS Lett. (2013) 587:1247–\n57. doi: 10.1016/j.febslet.2013.01.047\n298. Li X, Lu F, Wang J-Z, Gong C-X. Concurrent alterations of O -GlcNAcylation\nand phosphorylation of tau in mouse brains during fasting. Eur J Neurosci.\n(2006) 23:2078–86. doi: 10.1111/j.1460-9568.2006.04735 .x\n299. Guo T, Noble W, Hanger DP. Roles of tau protein in health and dis ease. Acta\nNeuropathol. (2017) 133:665–704. doi: 10.1007/s00401-017-1707-9\n300. Guillozet-Bongaarts AL, Cahill ME, Cryns VL, Reynolds MR, Berry RW,\nBinder LI. Pseudophosphorylation of tau at serine 422 inhibits ca spase\ncleavage: in vitro evidence and implications for tangle formation in vivo. J\nNeurochem. (2006) 97:1005–14. doi: 10.1111/j.1471-4159.2006.03784 .x\n301. Kimura T, Sharma G, Ishiguro K, Hisanaga S. Phospho-tau bar code : analysis\nof phosphoisotypes of tau and its application to tauopathy. Front Neurosci.\n(2018) 12:44. doi: 10.3389/fnins.2018.00044\nFrontiers in Neurology | www.frontiersin.org 23 January 2021 | Volume 11 | Article 595532\nAlquezar et al. PTMs as Dynamics Transformers of Tau Homeostasis\n302. Mair W, Muntel J, Tepper K, Tang S, Biernat J, Seeley WW,\net al. FLEXITau: quantifying post-translational modiﬁcations of\ntau protein in vitro and in human disease. Anal Chem. (2016)\n88:3704–14. doi: 10.1021/acs.analchem.5b04509\n303. Hanger DP , Byers HL, Wray S, Leung KY, Saxton MJ, Seereeram A, et al.\nNovel phosphorylation sites in tau from Alzheimer brain support a role\nfor casein kinase 1 in disease pathogenesis. J Biol Chem. (2007) 282:23645–\n54. doi: 10.1074/jbc.M703269200\n304. Dammer EB, Lee AK, Duong DM, Gearing M, Lah JJ, Levey AI, et al.\nQuantitative phosphoproteomics of Alzheimer’s disease reveals cross -talk\nbetween kinases and small heat shock proteins. Proteomics. (2015) 15:508–\n19. doi: 10.1002/pmic.201400189\n305. Kang MJ, Kim C, Jeong H, Cho BK, Ryou AL, Hwang D, et al. Synapsi n-1 and\ntau reciprocal O-GlcNAcylation and phosphorylation sites in mouse brai n\nsynaptosomes. Exp Mol Med. (2013) 45:e29. doi: 10.1038/emm.2013.56\n306. Hanger DP , Betts JC, Loviny TLF, Blackstock WP , Anderton B H.\nNew phosphorylation sites identiﬁed in hyperphosphorylated\ntau (Paired helical ﬁlament-tau) from Alzheimer’s disease brain\nusing nanoelectrospray mass spectrometry. J Neurochem. (2002)\n71:2465–76. doi: 10.1046/j.1471-4159.1998.71062465.x\n307. Doll S, Burlingame AL. Mass spectrometry-based detection and as signment\nof protein posttranslational modiﬁcations. ACS Chem Biol. (2015) 10:63–\n71. doi: 10.1021/cb500904b\n308. Theillet FX, Smet-Nocca C, Liokatis S, Thongwichian R, Kost en\nJ, Yoon MK, et al. Cell signaling, post-translational protein\nmodiﬁcations and NMR spectroscopy. J Biomol NMR. (2012)\n54:217–36. doi: 10.1007/s10858-012-9674-x\n309. Singh S, Springer M, Steen J, Kirschner MW, Steen H. FLEXIQua nt:\na novel tool for the absolute quantiﬁcation of proteins, and the\nsimultaneous identiﬁcation and quantiﬁcation of potentially mod iﬁed\npeptides. J Proteome Res. (2009) 8:2201–10. doi: 10.1021/pr80\n0654s\n310. Wesseling H, Mair W, Kumar M, Schlaﬀner CN, Tang S, Beerepoot P , et al.\nTau PTM proﬁles identify patient heterogeneity and stages of Alzhe imer’s\ndisease. Cell. (2020) 183:1–15. doi: 10.1016/j.cell.2020.10.029\nConﬂict of Interest: The authors declare that the research was conducted in the\nabsence of any commercial or ﬁnancial relationships that could be c onstrued as a\npotential conﬂict of interest.\nCopyright © 2021 Alquezar, Arya and Kao. This is an open-access art icle distributed\nunder the terms of the Creative Commons Attribution License (CC BY). The use,\ndistribution or reproduction in other forums is permitted, p rovided the original\nauthor(s) and the copyright owner(s) are credited and that th e original publication\nin this journal is cited, in accordance with accepted academ ic practice. No use,\ndistribution or reproduction is permitted which does not co mply with these terms.\nFrontiers in Neurology | www.frontiersin.org 24 January 2021 | Volume 11 | Article 595532"
}